



# ACS OMEGA

[pubs.acs.org/acsomega](http://pubs.acs.org/acsomega)

Volume 6, Issue 28

July 20, 2021



# Boronic-Acid-Modified Nanomaterials for Biomedical Applications

Yu-Yu Aung, Alfinda Novi Kristanti, Hwei Voon Lee, and Mochamad Zakki Fahmi\*

Cite This: *ACS Omega* 2021, 6, 17750–17765

Read Online

ACCESS |



Metrics &amp; More




Article Recommendations



Supporting Information

**ABSTRACT:** Boronic-acid-modified nanomaterials have inspired significant research interest owing to their unique biocompatibility and excellent reversible interaction with diol groups containing saccharides, protein, DNA, and other related glucose compounds. However, the different sources and methods change the application of nanomaterials. Thus, surface-functionalized nanomaterials are of interest as one of the best ways to improve the application of the biomedical field. In this mini-review, we summarize recent studies on boronic-acid-modified nanomaterials, based on the carbon dot group and graphene oxides, which have been used in the fields of bioimaging, biosensing, antiviral inhibitors, etc. Moreover, the multivalent interaction on boronic-acid-modified materials has become the main key improvement for targeting treatment in the future. We mainly focused on any previously reported papers for synergistic future opportunities of superior biomedical applications of carbon dots (CDs) in the management and diagnostics of nanomedicine fields.



## 1. INTRODUCTION

Carbon is generally exhibited as an allotropic structure. The carbon dot (CD) group consists of carbon quantum dots (CQDs), graphene quantum dots (GQDs), and polymer dots (PDs). Various sources of carbon and synthesis methods have been applied to prepare the CDs, and the resulting CDs' structures are also diverse.<sup>1</sup> Each type of carbon family has interesting features and has been widely exploited in biological applications due to their unique properties, such as chemical inertness, excellent fluorescence emission, water solubility, low toxicity, photobleaching resistance, high luminescence, optical absorption, and high conductivity.

For biomedical concepts, the design of a material that is specific to the biological target was the most crucial aspect besides the toxicity issue. Although lethal dose consumption as high as commercial salt is well known, boron and its derivative compounds became favorable elements for theranostic studies of the biological environment. Among the other boron derivative compounds, many researchers have reported the utilization of boronic acid functionalized onto nanoparticles for many applications. Recently, various boronic-acid-modified nanomaterials have been applied in biomedical applications, containing selective separation of glycopeptides and glycoproteins, therapeutic agents for cancer therapy, boron neutron capture therapy, sensing, hydrogels, and diabetes.

In aqueous media, the Lewis acidity of boronic acid can interact with other Lewis-base sites, which produce the boronate anions and sufficiently bind to *cis*-diol groups containing saccharide compounds such as glucose, mannose, and adenosine triphosphate (ATP). This opened a new avenue to using boronic acid as a specific targeting ligand to biorelated compounds like sialic acid and glycoprotein groups in the

various cells. Various boronic acid derivatives were reported to be utilized for saccharide detection and to treat a cancer cell line via a sialic acid connection. Considering HIV infection, the strong *in vivo* interaction between the gp120 immunogens on the HIV-1 surface and the CD4 receptor has been reported, which results in conformational changes that alter the immunogenicity of the glycoprotein subunit. This was highlighted through special binding of gp120 to the CD4 receptor directly. Therefore, many researchers paid intensive research attention to the boronic-acid-modified materials that indirectly block the CD4 binding by changing the gp120 substructure or disturb the stability interaction of gp120 and CD4. Regarding the above information, the boron-modified nanomaterials brought attractive potency to biomedical applications, even still on limited and nonintegrative reports. Moreover, evaluation of carbon dots attributed to boronic acid has never been explored, and there are remaining questions to discuss regarding their benefits. Therefore, in the present mini-review, we focus first on digging into information on the performance of boron, its derivative, and carbon dots (including CQDs, GQDs, and PDs). Also, we further focus on the advanced potential application of boronic-acid-modified carbon dots. The discussion next explores any application reports of boronic-functionalized carbon dots with its work mechanism for bioimaging, biosensing, glucose sensing, HIV inhibitors,

Received: March 13, 2021


Accepted: June 15, 2021

Published: July 6, 2021



bioimaging of cancer therapy, and antiviral inhibitors as the main focus of applications (Scheme 1).

**Scheme 1. Boronic-Acid-Modified Carbon Dots (CQDs, GQDs, and PDs) for Biomedical Applications**




**1.1. Boron.** Boron is part of a semiconductor organization in elemental groups. The ability of boron is intermediate among metals and nonmetals. This element can be found in nature with certain oxygen and is never found in pure elements. There are two types of nonradioactive isotopes of boron,  $^{10}\text{B}$  and  $^{11}\text{B}$ , which are naturally found in the Earth's crust. The small atom of boron has three valence electrons, allowing its electrons to covalently bond with other elements or molecules to fill its outer shell. The vacant p-orbital on boron acts as a Lewis acid and interchanges from  $sp^2$  to  $sp^3$ , allowing it to capture other Lewis bases. This interchanging can also be quickly made by interacting with water in an aqueous solution. In neutral conditions,  $sp^2$  hybridization of boron is transferred to an anionic  $sp^3$  hybridization form in equilibrium<sup>2</sup> (Scheme 2a).

Boron can be found abundantly in nature as boric acid due to its strong attraction to oxygen as organoboron. Any organoboron is capable of combining with biological materials including polysaccharides. As part of organic molecules, boric acid and borane molecules are found in tissues, fluids, and blood in the human body. By the hydrolyzing process of borane, boronic acid can be produced along with other boron compounds such as boric acid, boronic ester, and boroxine. The family of boron-containing organic compounds as organoboron compounds is shown in Scheme 2b. Boronic acid is a trivalent organic molecule containing boron, which bonded two hydroxyl groups and one alkyl/aryl substituent group to occupy the valence electrons in the atom of boron, making it more stable than a borane. For boronic acid, it can bind with polysaccharides and other ionization transition materials for diabetes diseases and other biomedical applications including cancer therapy, antiretroviral therapy, sensing, and catalysts.<sup>3</sup> These were considered to be due to the fact that boronic acids perform trigonal planar to form a boron atom, which donates a bond with a group of alkyl substituents as well as with two hydroxyl groups in neutral aqueous solution.

**1.2. Reactivity of Boronic Acid.** Since the late 19th century, the ability of boronic acid to interact with sugar alcohol groups has been recognized, and the detailed interactions

**Scheme 2. (a) Transfer in Geometry to the Center of Boron on an Interaction with a Nucleophile, (b) Various Oxygenated Organoboron Compounds, and (c) Esterification Equilibria of Boronic Acid in Aqueous Solution<sup>4</sup>**




<sup>4</sup>Adapted with permission from refs 3 and 2. Copyright 2006 John Wiley & Sons. Copyright 2011 Elsevier.

involving diol moieties in the early 20th century have also been reported. Boronic acid is analogous with carboxylic acid, which can serve as a proton donor. However, they act as Lewis acids with hydroxide anions or fluoride or as electron-donating groups, such as oxygen or nitrogen. In aqueous solution, the acid property of boronic acid increases as it interacts with 1,2- or 1,3-*cis*-diols to form cyclic boronic ester (Scheme 2c).<sup>4</sup>

The neutral form of boronic acid exhibits  $sp^2$ -hybridized boron (trigonal planar) and two hydroxyl groups. The formation of boronate esters has reversible molecular assemblies with the boronic acid and diol groups under the actual conditions. This is a beneficial interaction for saccharide reaction because it forms cyclic boronate ester, as exhibited on the complexation between boronic acids (Lewis acids) and proximal tertiary amines (Lewis bases). The precise character of boron–nitrogen (B–N) interplay has been reported to provide two advantages. First, at neutral pH, the B–N interaction is enhanced by the formation of a tetrahedral boronate complex, which allows strong binding to a particular target with chemical interaction. Second, the B–N interaction enhances binding due to the Lewis acid feature from the boron atom, and it modulates fluorescence property by moving the photoinduced electron from the nitrogen and stabilizing the obtained structure of the B–N interaction. In particular, the Lewis acidity of the boron atom increases the electron-withdrawing character, and the Lewis base of nitrogen increases electron-donating character. Wulff and co-workers revealed that the boronic acid's  $pK_a$  value decreased through the intramolecular coordination of the boron-supplied nitrogen atom and the boron with an oxygen atom (Scheme 3a).<sup>5</sup> This observation showed that the dative bond was formed between boron and nitrogen atoms, changing

**Scheme 3. Main Boronic Acid Interactions Concerning the Self-Assembly (a) and Intramolecular Interaction between Boronic Acid and a Nitrogen Atom (b)<sup>a</sup>**



<sup>a</sup>Adapted with permission from refs 5 and 4. Copyright 2016 American Chemical Society. Copyright 2013 American Chemical Society.

the hybridization type of the boron, from  $sp^2$  to  $sp^3$ , which forms the fast and more stable bond formation boronate esters. The dative B–N bond is usually favored on protic media like water or methanol. However, this protic solvent insertion prepares a hydrogen-bonded zwitterionic species, which can contribute to enhancing the binding of *cis*-diols at pH-neutral conditions.<sup>5</sup> The complexation of the dative bond between boron and nitrogen is extremely influenced by some aspects, like containing the structure of boronic acid, steric hindrance on the nitrogen atom, various solvents, different concentrations of diols, and different pH solutions. The substitution of bulky groups was also reported to influence the dative bond (B–N) formation by decreasing the binding strength between the boron and nitrogen atom. Boronate ester formation is highly dependent on the various pH conditions and the solvent used. At low pH conditions, the amine group protonated to the boron center and changed to trigonal planar  $sp^2$  hybridization. Therefore, the boron center of boronic acid interacted with a hydroxide anion and released nitrogen at higher pH conditions. After that, in neutral pH conditions, the nitrogen atom deprotonated and coordinated with the boron center of boronic acid and transferred to a tetrahedral boronate anion. Boronate ester formation appears with a higher  $pK_a$  of boronic acid. It can interact immediately and reversibly with groups of *cis*-diol to make a boronate ester compound due to the basicity of the liquid system (Scheme 3b).

The above discussion informed us that the boronic acid site was revealed to be an excellent binding agent with another nucleophilic substance, such as dicarboxylic acids and  $\alpha$ -hydroxy-carboxylic acids. Boronate ester formation was favored for the analysis of saccharides, glycoprotein detection, glucose sensing, HIV barriers, and staining along with cancer therapy, and it is discussed in the following section.

### 1.3. Unique Features of Boron-Based Nanomaterials.

Boron-based nanomaterials have been one of the most researched until recently. These nanomaterials are extensively used as chemical functional groups for biomedical applications. Boron-based nanomaterials possess diverse great advantages

such as chemical stability, excellent optical performance, and good biocompatibility. Under these conditions, boronic acid acts as a Lewis acid and interacts with vicinal diol groups to generate boronate esters. In addition, they can react with various precursors of disease such as the saccharide group, glycoprotein, and sialic acid as targeting agents. Therefore, they can be applied for bioimaging and inhibition of targeting materials after suitable creation of the nanoparticle's surface. Boronic acid moieties on the nanoparticle surface act as reactive oxygen species (ROS), pH-responsive groups, diol-responsive nanomaterials, and targeting agents. By using  $H_2O_2$ , the hydroxyl groups containing dextran from 4-(hydroxyl methyl) phenylboronic acid pinacol ester changed to a hydrophobic dextran form, which has been applied for ROS-responsive cargo release in vitro and in vivo. In addition, due to regular cellular metabolic activity, the pH value is stable and regulated in our body. However, the metabolism process changed into an abnormality in the regulation of pH levels from pathological environments such as cancer and diabetes. In this context, a class of pH-responsive boronate–cross-linked polysaccharides displayed water solubility and biocompatibility, which can be effectively used in specific targeting (pH-dependent targeted drug delivery system) for cancer treatment. In addition, boronic-acid-based nanomaterials effectively linked with 1,2- and 1,3-containing glucose, fructose, galactose, gp 120, and ribose in a neutral pH medium. Also, they act as a neutral specific targeting agent for a glucose sensor and HIV inhibitor due to their size and structure. Similarly, boronic-acid-modified nanomaterials interact with sialic acid on the HeLa cancer cell due to their ester ring formation and reversible covalent interaction. Hence, the boronic-acid-modified nanomaterials are widely useful for cancer imaging and diagnosis.

## 2. CATEGORIES AND SYNTHESIS OF NANOPARTICLES

As in boronic acid moieties, nanoparticles can also exhibit interesting features that may be totally different from the bulk phase. Investigations of the interactions of nanoparticles within



clinical research, diagnostics, and therapy with biomolecular compounds have existed for a long time due to their superior electrical and optical properties and morphology. In particular, nanoparticles have been improved as biomolecules with specific targeting agents for optical imaging and as sensors for detection of polysaccharides and drug delivery to specific cell lines (e.g., cancer and inhibition of HIV and viral infection). Nanoparticles have also been synthesized using various methods for biomedical applications, which can adjust their size and structure in terms of their physicochemical activities. Generally, the most popular nanoparticles for biomedical applications are carbon-based nanoparticles such as fullerene, carbon nanotubes, carbon dots (CDs), carbon quantum dots (CQDs), graphene quantum dots (GQDs), and polymer dots (PDs), which are of intense interest, as demonstrated by their ability to successfully penetrate a cell membrane and tissues because of their small size, high surface area, enhanced mechanical properties, and ease of modification with functional groups on the quantum dot surface.<sup>1</sup> Nowadays, there are two approaches for preparing functional carbon dots, namely, “top-down” and “bottom-up”. With the former, the carbon dots are designed from larger carbon cluster structures by using methods such as arc discharge, laser ablation, electrochemical oxidation, etc. In the “bottom-up” approach, the production of CDs on the surface of CDs can easily possess a large number of functional groups by using bottom-up methods, including the hydrothermal method, microwave-assistance method, ultrasonic method, and pyrolysis method.

Researchers reported numerous kinds of carbon-based fluorescent materials such as carbon dots (CDs), carbon nanodots (CNDs), graphene quantum dots (GQDs), carbon quantum dots (CQDs), and polymer dots (PDs), and so on.<sup>1</sup> Due to overlap and conflict separation of the various CD families, unification and standardization are important for further improvement of CDs. As fluorescent nanomaterials are developed, the analysis of fluorescent behaviors of CDs was still improved although challenging.

**2.1. Classification of Reported CDs.** As part of nanoparticles, CDs are a family of quantum dots that are semiconductor nanoparticles commonly coated by a capping ligand as a passivating agent to maintain its colloidal stability. For typical QDs, when this material has a size diameter that is smaller than the radius of the Bohr exciton, the PL properties are essentially dominated by the quantum confinement effect. Therefore, the size of quantum dots (QDs) depends on the exciton confinement. The regulation of intrinsic energy levels on QDs correlated to particle size, and the doping process, along with the surface effect, correlated to defects and ligands. Therefore, the homogeneous size distribution of QDs exhibits excitation-independent emission and narrows the full width half-maximum.<sup>6</sup> QDs composed with active elements have been widely used in a variety of devices and applications. The common QDs are prepared from II–VI or III–V element groups, which have been significantly developed in biological science and clinical applications. Therefore, they can act as valuable luminescent probes in drug delivery and specific targeting, glucose sensing or glucose detection, and bioimaging.

On the other hand, carbon dots (CDs), as developing fluorescent nanomaterials, possess at least one-dimensional shape less than 10 nm in size and excellent fluorescence as distinct optical properties. The structure of CDs exhibits a pure carbon core as an  $sp^2/sp^3$  carbon and surface passivation group (oxygen/nitrogen-based groups) or various polymeric pre-


cursors. The optical properties of CDs were correlated with  $sp^2/sp^3$  features from carbon and oxygen/nitrogen-based groups. The fluorescent CDs are classified into three types, namely, GQDs, CQDs, and PDs. All types of CDs create a new class of semiconductor nanoparticles with ultrasmall size (2–10 nm) and similar photoelectrochemical properties, but they differ in the internal construction and functional groups on the surface due to their specific properties, such as water stabilities, chemical stability, biocompatibility, and low toxicity. The types of CDs are discussed below.

**2.1.1. Graphene Quantum Dots (GQDs).** From their typical structure, GQDs exhibit a graphite structure of less than five layers and are correlated with functional groups on their edges, which are anisotropic and make them become an ultrasmall two-dimensional material. The triple carbene from zigzag edges, oxygen-based groups, and resonance properties of amine groups are exhibited on the surface/edge state of a graphene sheet. Diverse types of edges, armchair and zigzag edges, can be obtained, after cutting the graphene sheet along different crystallographic directions. As a result, the GQDs can be ideal to analyze the photoluminescent (PL) mechanism of CDs. In this context, the chemical PL process is derived from the graphene oxide (GO) because the GO is mainly used as raw molecular particles for the preparation of GQDs. In addition, the chemical structure of GO and GQDs is similar. Therefore, the aromatic  $sp^2$  domains on the GQDs exhibited a linearly aligned epoxy and  $sp^3$  C–O (hydroxyl bond) structure.

**2.1.2. Carbon Quantum Dots (CQDs).** CQDs have spherical structure and amorphous nature (if crystallinity shows a lattice parameter up to 0.24 nm), which contain a  $sp^2/sp^3$  carbon core and rich oxygen. CQDs possess a multiple-layer graphite structure with the same horizontal and vertical dimensions that made it different from the planar structure of GQDs, which set graphene as the main structure with a honeycomb lattice of carbon atoms and  $sp^2$  hybridization carbon structure.<sup>6</sup> In this regard, CQDs are suitable for chemical modification and surface passivation using organic or inorganic molecules, diverging polymers, and biological materials. Therefore, CQDs have been effectively developed by surface passivation. Also, due to the various molecules, the surface energy traps controlled the PL mechanism of CQDs.

**2.1.3. Polymer Dots (PDs).** PDs, generally named polymer CDs, have also been reported as a new structure of the CD family. The structure of PDs consists of either polymeric cross-linked/aggregated polymer chains or linear polymer chains assembled around the spherical carbon. However, a vast majority of PDs are a tangled coil, which consisted of high cross-linking and a hydrophilic chain on the external PD surface. PDs further enhanced the fluorescence emission due to the highly cross-linked enhanced emission effect, which described the excellent emission in their species nonconjugated polymer structure. The PL of the PD nanoparticles can have a diverse lifetime, and the intensity of the emission wavelength depends on their surface group, size, and structure. Due to the carbonization, the chemical stability of PDs is better than that of simple polymers. Also, the aggregated polymer chain provided better compatibility of PDs than that of QDs. This proves that the correlation between the polymer and carbon core brings about advantages for the development of eco-friendly materials due to the nontoxic and low-cost properties of these materials.

**2.2. Synthesizing the CD Nanoparticles.** Table S1 (Supporting Information) lists many reports that successfully



**Figure 1.** Synthesis process of the fluorescence properties of B-doped carbon dots (CDs) on both aqueous and solid conditions. Photograph courtesy of C. Shen. Reprinted with permission from ref 8. Copyright 2015 Royal Society of Chemistry.


obtain CDs with divergent synthesis methods such as hydrothermal, laser irradiation, microwave assistance, pyrolysis, electrochemical, and cross-linking and assembly methods, which summarize the advantages and disadvantages by using different methods. These results indicated an ease of preparing CDs. Therefore, we can easily understand from Table S1 that one of the most common organic precursors is prepared from the hydrothermal or solvothermal method. Their advantages and disadvantages create restrictions for further applications. As a result, the achievement for further synthesis design is the physical form, and it should produce uniform size, easy modification, and high QY. Even so, the hydrothermal method was widely utilized because it is effective and fast and has low cost, biosafety, and environmental friendliness. Therefore, we discuss the as-prepared boron-based nanoparticles by using hydrothermal/solvothermal methods in the next section of this mini-review.

**2.3. Current Strategy for the Synthesis of Boron-Based Nanoparticles.** So far, the synthetic methods for the preparation of CDs have been established into two main approaches: “top-down” and “bottom-up” routes. Both approaches exhibit inherent benefit. Nevertheless, surface passivation or functionalization for the synthesis of CDs usually needs the next step through “top–bottom” methods. Compared with the “bottom-up” methods, no next step is necessary, and the functionalization can be established in a “one-step” hydrothermal method. Hydrothermal methods are simple and easy to functionalize due to their good synthetic control and good size control, and the hydrothermal method has the advantage of creating the properties of carbon-based nanoparticles. To improve the optical properties as fluorescent properties, both the surface functionalization and heteroatom doping are the most effective ways to do so for carbon-based nanoparticles such as CDs, GQDs, CQDs, and PDs. By heteroatom doping (B, N, S, and P), the intrinsic properties as electronic properties, optical properties, and surface reactivity are effectively influenced on the nanoparticles. Many researchers have investigated improving the optical, electrical, and chemical properties of nanoparticles by introducing the heteroatoms. Due to their electronic structure, CDs can be adjusted, creating n-type or p-type carriers. Hence, by utilizing certain types and amounts of doping materials, the optical and electronic properties of carbon nanoparticles can be tuned. Although nitrogen is widely used for doping processes, it is unstable in the carbon skeleton at high temperature. Therefore, using boron atom doping into the carbon-based nanoparticles, the ionic charge (positive and negative) was effectively balanced in the carbon skeleton of the nanoparticles. For instance, our previous report showed that heteroatom doping of carbon dots was performed by a one-step furnace and microwave-assisted method with high QY. Compared to the heteroatom (B, N, S, and P) carbon dots, the boron-doped carbon dots displayed the


highest photoluminescence (QY = 32.96%) and low toxicity (above 80%) and demonstrated bioimaging with strong emission in the cytoplasm of HeLa cancer cells. Besides, doping and functionalization of carbon dots effectively used the hydroxyl group containing boron derivative compounds as boric acid and boronic acid, respectively.<sup>7</sup> In this condition, the boronic acid ( $\text{B-(OH)}_2$ )-based carbon nanoparticles anticipated correlation with polysaccharide groups such as mannose, gp 120, and sialic acid on the host cell membrane, which can help us understand the inhibition of the viral mechanism. Therefore, very recently researchers have demonstrated boron doping and functionalization of carbon nanoparticles with CDs, CQDs, GQDs, and PDs by using one-pot synthesis as hydrothermal/solvothermal methods.

**2.3.1. Hydrothermal/Solvothermal Synthesis.** Although there are diverse ways to prepare heteroatom-doped carbon-based nanoparticles, hydrothermal/solvothermal methods are widely adopted due to their eco-friendliness, ease of operational control, high efficiency, and one-step process. In a typical synthesis, the precursors, a mixture of small organic molecules, are dissolved with solvent and transferred to a Teflon-lined stainless steel autoclave by heating at a high temperature of approximately 100–270 °C for suitable hours. At that time, all of the small molecules interact together to change carbonaceous structure and form into CDs with a size range from 2 to 10 nm. As previously reported, the synthesis of CDs using hydrothermal/solvothermal methods with a divergent boron source is summarized in Table S2 (Supporting Information). The QY can be enhanced by using suitable experimental conditions such as varying boron source, solvent nature, heating time, and temperature. For instance, Shen and co-workers<sup>8</sup> adopted the hydrothermal process and prepared the B-doped carbon dots (CDs) with boric acid and ethylenediamine, which have good solubility and excellent fluorescence on both aqueous and solid conditions (Figure 1). B-doped CDs’ fluorescence was well controlled at yellowish-green emitted light in the solid state. Note that the above-explained synthesis strategies of CDs applied cell (cellular) imaging in the living cell. It has less toxicity and higher fluorescent staining property in living cells. Some B-doped CDs have also been an effective strategy for the metal-free electrocatalyst for the oxygen reduction reaction (ORR). Modifying the surface of carbon dots with boron reveals that the B atoms are incorporated with a positive charge on the carbon atom because their electronegativity is lower than that of C atoms.

By combining the graphene oxide (GO) and BGQD, we show the metal-free electrocatalyst for ORR. It has excellent operational stability for a long time and a strong ability to tolerate methanol crossover effectively and has the potential to be applied as a substitute for the Pt-based catalyst in ORR as well as other electrochemical applications. Moreover, Xu et al. found that the synthesized BCQDs with 3-pyridine boronic



**Figure 2.** Process of the B-CD synthesis for the detection of SA. Adapted with permission from ref 9. Copyright 2019 Elsevier B.V.



**Figure 3.** Synthesis process of the CPBA-CDs as nanosensors for catechol based on CPBA-CDs. Adapted with permission from ref 10. Copyright 2017 Elsevier B.V.


acid are much better for the determination of SA (Figure 2).<sup>9</sup> BCQDs were prepared by a one-step hydrothermal process and were effectively used for determination of SA with a linear range from 80  $\mu\text{M}$  to 4000  $\mu\text{M}$  ( $R^2 = 0.992$ ) with a LOD value at 54  $\mu\text{M}$ . It should be noted that BCQDs could successfully monitor the SA concentration in samples of human serum with sufficient data. In addition, the CDs can be applied as a dopamine (DA) biosensor for the detection of dopamine on the solid surface. Covalently linked CDs are beneficial to better adjust the size, form, physical properties, and chemical properties of the CD surface.

The application of boron-doped CDs for the detection of specific compounds was also observed by Ye et al., who synthesized the 4-carboxyphenylboronic-acid-functionalized carbon dots (CPBA-CDs) by a one-pot hydrothermal method by applying anhydrous citric acid (CA) and diethylenetriamine (DETA) as the source of carbon and 4-carboxyphenylboronic acid as a functionalizing agent.<sup>10</sup> In addition, CPBA-CDs have effectively examined the catechol concentration. In various concentrations of catechol, boronic acid functional sites on the carbon dot surface react with the vicinal diols of catechol molecules, which formed the borate ester structure (Figure 3). The functionalization of CPBA-CDs found that they could be used in human umbilical vein endothelial cells and that they are mostly applicable for multicolor real-time cell staining.

By hydrothermal reaction, Jiang et al. fabricated boronic-acid-functionalized N-doped carbon quantum dots (APBA-NCQDs) from a collagen and ammonia solution, continued with modification using 3-aminophenylboronic acid (APBA)

grafting as a glucose sensor (Figure 4).<sup>11</sup> APBA-NCQDs showed sensitivity and selectivity to fluorescent quenching properties and have been effectively applied in glucose detection and diabetes diagnostics.

The as-prepared N-B-GQDs demonstrated in vivo NIR-II imaging and used the internal organ of mouse model. The fluorescence properties of N-B-GQD nanoparticles were capable for use in imaging-related cancer therapy and



**Figure 4.** Synthesis process of the fluorescent behavior of APBA-NCQDs with and without the presence of glucose. Reprinted with permission from ref 11. Copyright 2014 IOP Publishing Ltd.




monitoring. They displayed great fluorescence intensity with quantum yield and excellent stability. All the above-mentioned studies showed the interference of doping atoms on the natural emission of CDs. Although the fluorescent CDs have relatively low QY, they can be effectively used in cell imaging for sensors.

### 3. BORONIC-ACID-MODIFIED NANOMATERIALS FOR BIOMEDICAL APPLICATIONS

The advantages of boronic acid and CDs as part of nanoparticles open the possibility for this material to be combined to promote multipurpose applications. On further discussion, several reports on using boronic-acid-modified nanomaterials were presented for biological application.


**3.1. Bioimaging.** To date, carbon dots have been used as bioimaging agents to label into many cells because they are strong, stable, and highly PL. Under these conditions, the size and surface states of carbon dots greatly influence their PL properties. Table S3 (Supporting Information) summarizes the boron-containing carbon dots as a staining agent in various cell lines for cell imaging and cancer treatment. Due to their high photostability and resistance to photobleaching, carbon dots successfully stained the cell lines under prolonged illumination. It is interesting that even though the carbon dots surface is passivated with substituent groups their luminescent properties are not lost. However, many studies investigated how to improve the PL properties by using chemical modification. For example, Liu et al.<sup>12</sup> reported staining of sialic acids on live cells with a novel class of imaging probes on the basis of phenylboronic-acid-doped quantum dots. Quantum dots showed that they could be efficiently one-step labeled and simultaneously interacted with the sialic acid moieties of the cell's surface with no treatment of living cells. For labeling design, the QDs entered endocytic pathways together with SA into the PC12 cells for different times (10–90 min), where the amount of the quantum dots (QDs) was combined with the cell membrane and formed a ring-fluorescent shape after 10 min of incubation (shown in Figure 5). The APBA-QDs were gradually internalized and displayed bright color in the intracellular scope even under a longer incubation time from



**Figure 5.** Confocal images of PC12 cells that were incubated using APBA-QDs and the intracellular dissemination of QD-labeled SA using various times: (a) 10 min, (b) 20 min, (c) 60 min, and (d) 90 min. Reprinted with permission from ref 12. Copyright 2010 American Chemical Society.

20 to 60 min, and then over 60 min, the spread emission did not change in the cell, undertaking longer incubation time.

More remarkable progress was reported by Zhang and co-workers who reported the functionalized graphitic carbon nitride quantum dots (PCQDs) from 3-aminophenylboronic acid (APBA) through Schiff base reaction at 180 °C for 60 min.<sup>13</sup> The results indicated that PCQDs could efficiently and selectively label sialic acids on living cells and tissue, with a size range of 3–5 nm. Due to the abundant passivity by PBA on the structure of PCQDs, it could be more soluble in water and efficiently strained in distinct cell lines (H460, BEAS-2B, and Jurkat T cells) within 30 min. In Figure 6, the confocal images




**Figure 6.** Confocal laser scanning images of H460 cells that were incubated with PCQDs (50 mg/mL) for various times: 30 min, 2 h, 6 h, and 10 h. Reprinted with permission from ref 13. Copyright 2019 Elsevier B.V.

of H460 cells stained with PCQDs revealed an interplay between probes and the target at varied times. After incubation for 30 min, the PCQDs were mostly bound to the cell membrane. The PCQDs are still labeled on the surface of cells even under prolonged incubation from 2 to 10 h. The QY% values of the PCQDs are also diverged due to their synthetic mechanism and structure. Note that PCQDs possessed strong stability and high QY%, which efficiently probed for labeling to the SAs on the cancer cell.

In addition, the existence of heteroatomic doping on CDs opens a change to the complex structure with a particular element. Thus, it can be modified as a nanosensor based on fluorometric as well as colorimetric assays with specific metal ions (such as  $\text{Fe}^{3+}$ ). In particular, carbon dots could be used for sufficient determination of  $\text{Fe}^{3+}$  with a notable sensitivity ranging between 0.3 and 546  $\mu\text{M}$  with a detection limit value of 90 nM, which is supported by the quenching of red fluorescent emission as shown in Figure S1 (Supporting Information). Nevertheless, the cell imaging experiments noted that the red fluorescence BNS-CDs can serve in the investigation of intracellular  $\text{Fe}^{3+}$ . Another study on modifying CDs with boron was proposed by Ngo et al., in which the higher fluorescent aminoboronic-acid-functionalized graphitic carbon nitride quantum dots (g-CNQDs/3APBA) exhibited labeling fluorescent potency in the cells. After being incubated with g-CNQDs/3APBA for 8 h, the HeLa cells released bright blue and green emission colors at 405 and 488 nm excitation.<sup>14</sup> The




fluorescent emission of g-CNQDs/3APBA was shown in the cell membrane and cytoplasmic part of the cells in Figure 7. The




**Figure 7.** Confocal laser scanning images of HeLa cells with g-CNQDs/3APBA under excitation wavelengths of 405 nm (A) and 488 nm (B). Reproduced with permission from ref 14. Copyright 2019 Elsevier Ltd.

g-CNQDs/3APBA is not able to strain into the inside of the nucleus, even though it can enter into the nuclei, which makes it show low cytotoxicity and exhibit excellent bioimaging properties on the living cell surface.

In addition, boron-doped carbon nanoparticles (B-CNPs) were used to label cells because they have different diameters and size-dependent fluorescent color (red to blue). For the cell labeling experiment, HeLa cells were incubated with 30  $\mu\text{L}$  of BCQDs (BC-31, BC-61, and BC-101) in the MEM medium for 5h. According to the cell imaging results, the HeLa cells with BC-101 (Figure S2d, Supporting Information) showed stronger fluorescence than BC-31 and BC-61 (Figure S2b and c). In Figure S2a, after the HeLa cells were incubated without BCQDs, the colorless images were observed. Although the QY of BCQDs was 0.5%, it could be applied well for bioimaging in HeLa cells. Investigation of a nanohybrid based on boron-doped carbon dots (BCQDs) active on both fluorescence and magnetic resonance (MR) was performed for imaging by Zhao et al.<sup>15</sup> BCQDs possessed great fluorescence intensity as well as higher longitudinal relaxivity ( $r_1 = 5.13 \text{ mM}^{-1} \text{ s}^{-1}$ ), which exhibited red-shifted fluorescence emission. Due to the high fluorescence intensity and relaxation rates of BCQDs, they were further investigated for imaging in HeLa cells and fluorescent MR imaging in nude mice. After incubation of the HeLa cells with BCQDs ( $30 \mu\text{g mL}^{-1}$ ) for 2 h, the cells showed bright green fluorescent emission under 458 nm excitation, which is in significant contrast with control cells where no fluorescence



**Figure 8.** (a) Confocal laser scanning microscopy bright-field and fluorescence images of HeLa cells with BCQDs (30 mg/mL) and without BCQDs (blank) for 2 h. (b) In vivo fluorescence and MR imaging (inset) images without injection using BCQDs (A) and after subcutaneous injection with B-CDs into nude mice. Reprinted with permission from ref 15. Copyright 2019 Elsevier B.V.




**Figure 9.** Confocal microscopy images showing HeLa cells incubated with CCM (a) and free CDs (b) for 1 h. Confocal microscopy images showing HeLa cells incubated with DCCM for 20 min (c) and 1 h (d). Reprinted with permission from ref 16. Copyright 2015 Royal Society of Chemistry.

color appeared (Figure 8a). For *in vivo* imaging, after nude mice were injected with BCQD (200  $\mu$ L) solution, the MR images of the nude mice showed brighter fluorescence MR enhancement than the control conditions (Figure 8b). Zhao's group found that BCQDs with fluorescence and MR imaging properties can become true alternative beneficial agents for dual-modality imaging because of their low level of toxicity, good biocompatibility, as well as high contrast efficiency.

**3.2. Cancer Cell Imaging and Diagnosis.** Creating groundbreaking work, a targeted cancer investigation of various cell lines using boronic-acid-containing CDs has also been done. Recently, CDs were prepared as fluorescent probes by phenylboronic acid and citric acid (CA) and as precursors and utilized in cell imaging using HeLa cells. Due to the good water solubility and high quantum yield, the fluorescent imaging and microscopy displayed that the tiny CD nanoparticles could be internalized into the cell membrane. Nevertheless, this study suggests that CDs are suitable nanoparticles for bioimaging for future research. The CDs could be spread easily in the cytoplasm without the nucleus and agglomerated on the cell membrane.

Most of the research on applying the boronic acid moiety took advantage of forming boronate–diol bonding on the target with abundant hydroxyl groups. This feature will open a change in its application as a therapy and diagnostic (theranostic) tool simultaneously. In equivalent conditions, HeLa and B16F10 cells exhibited strong green fluorescence; however, there was no efficient fluorescence exhibited by NIH3T3 cells (Figure S3, Supporting Information). This study revealed that boronic acid worked with dual functions to increase the photoluminescent emission as well as drive the RCD1s-specific targeting on the cell. Additionally, boronic acid could be used as drug binding agent and deliver it as well. Therefore, the drug delivery of a pharmaceutical agent into the body could be done through a variety of approaches. Drug delivery systems (DDSs) using CDs have been used a lot for anticancer drug delivery. Doxorubicin (Dox), known as a commercial anticancer agent, works by inhibiting the DNA helix structure by stabilizing the

enzyme (topoisomerase II complex) within the replication system and thus destroying the cancer cell. For example, Fahmi et al. synthesized magnetofluorescent nanoparticles (NPs), which were modified with phenylboronic acid and conjugated to fluorescent carbon dots (CDs).<sup>16</sup> The as-prepared CD–phenylboronic-acid-modified nanoparticles with doxorubicin (Dox) in aqueous solution participated in doxorubicin delivery with HeLa cancer cells. The hydrophobic properties of  $\text{MnFe}_2\text{O}_4$  NPs were changed to hydrophilic materials by interaction with 4-carboxyphenylboronic acid molecules. The superior phenylboronic acid moieties were capable of interacting with a targeting specific cancer cell. Doxorubicin (Dox), a water-insoluble chemotherapy drug, was bound in magnetic nanoparticles (CCM) through  $\pi$ – $\pi$  stacking and hydrophobic interaction. Phenylboronic acid has a strong interaction ability with glycoprotein, including sialic acid, which is found on several pathologic cells. For *in vitro* investigation of fluorescent CCM and DCCM by confocal laser scanning microscopy, HeLa cells were used as a design cell line to examine the specificity on the cell surface (Figure 9). After incubation of the HeLa cells with the nanoparticles for 1 h, the CCM-treated cells had strong green fluorescence in the cell membrane according to the CLSM images (Figure 9a). In comparison with phenylboronic acid CDs with CCM, the CDs did not show strong fluorescence in the cytoplasm of HeLa cells (Figure 9b). The CCM is labeled into the cells through endocytosis mediated by a glycoprotein receptor. According to this result, boronic acid moieties on the CCM surface are capable of promoting intracellular uptake by receptor-mediated endocytosis. Dox connected to the surface of CCM particles to have a look at whether CCM is suitable for use as a carrier for delivering anticancer drugs. First, the HeLa cells were incubated with DCCM for 20 min, and the fluorescent images observed weak green and red fluorescence color. This result showed that DCCM cannot efficiently enter into the cells within a short incubation time (Figure 9c). After incubation for 1 h, the fluorescent green color was observed in the cytoplasm of cells (Figure 9d).



**Figure 10.** Schematic diagram of the synthesis process to fabricate boronic-acid-functionalized C-dots (A) and the interaction of CDs between boronic acid and *cis*-diol groups for glucose sensing (B). Reproduced with permission from ref 17. Copyright 2018 Elsevier B.V.

The boronic-acid-modified nanoparticles could interact with sialic acid moieties on the cancer cell surface, which was confirmed by a hemolysis assay. Moreover, the fluorescent CDs were attracted through an interplay between boronic acid and sialic acid moieties on the surface of the cancer cell.

**3.3. Biosensing.** It was well-noted on various applications that CDs have also been applied for fluorescent biosensing to examine such ions, biological pH value, protein, DNA, carbohydrates, enzymes, and vitamins. In the early state, the fluorescent properties of CDs were used to analyze biological sensors, and sensing was due to their intrinsic fluorescent properties. Furthermore, the surface modification gave excellent properties of a variety of CDs for sensing applications by transferring their surface functional groups, which act as a receptor or donor site. The features of the diverse sensors using boronic-acid-modified nanomaterials as sensor probes are discussed below.


**3.3.1. Fluorescent Sensing.** Traditionally, the fluorescent spectrophotometer is an extensively employed and attractive sensing technique for saccharide compounds according to their operational simplicity and high sensitivity. Interestingly, CDs can be applied in numerous fields, such as sensing and bioimaging, owing to their higher optical and fluorescent properties. In principle, the fluorescent properties of CDs are formed from the exciton radiative recombination. In theory, the fluorescence is produced from the conjugated domains in the bandgap transitions and the defected surface at the center of the carbonyl electron. The photoluminescence from CDs could be quenched well by either electron donor or electron acceptor molecules, which can efficiently enable nonradiative electron–hole recombination by an effective electron-moving process. Therefore, surface passivation or surface functionalization by doping with elements (boron, nitrogen, and sulfur) on CDs is one of the best ways to develop fluorescent features of CDs. The interaction of functionalized CDs influenced by biomolecules can exhibit the turned off–on feature, which is effective for detecting several biomolecules and improving the recovery of fluorescence. An interesting synergistic quenched effect of B-MoS<sub>2</sub> QDs toward dopamine (DA) by a coupling interaction was found. Boronic-acid-functionalized CDs were also often used to detect glucose for medical purposes because the sites of boronic acid on the surface of CDs will react to glucose diols. Currently, boronate affinity chemosensors are popular research topics in the field of glucose sensing. For instance, Zou et al. fabricated the boronic-acid-functionalized CDs to detect glucose concentration by sodium citrate and 3-

aminophenyl boronic acid as precursors. Their impressive work is based on enhancing synchronous fluorescence quenching and resonance light scattering (RLS) (Figure 10).<sup>17</sup> As mentioned above, the boronic acid moieties are assembled with the *cis*-diol group of glucose, which resulted in the aggregation state of fluorescence quenching on CDs and induced strong RLS enhancement. Accordingly, the CDs exhibited good emission at pH 6–8 within the excitation wavelength of 340 nm. Especially, the hybrid radiometric chemosensor was improved for facile and selective glucose sensing in the urine sample at pH 8. The CDs had great RLS enhancement properties at a glucose concentration (LOD) of 10 μM about their specific interaction, which leads to strong fluorescence quenching of CDs and can be efficient for quantitative glucose monitoring, due to its great sensitivity, wide linear response range, and decreasing cost. For great improvement, the CD-based sensing could also be efficiently applied for not only glucose detection but also nonenzymatic glucose sensing. The boronic-acid-modified CDs demonstrate a coupling interaction with the conjugated aromatic rings of CDs and boronic acid functional groups, which can exhibit excellent fluorescent enhancement and a blue shift effect.

Postsurface modification of GQDs created oxygen-rich CDs, and the GQDs possessed negatively charge anions, which easily conjugated with glucose to form negatively charged boronate complexes. Note that the electrostatic repulsion and covalently cross-linked interaction developed a counterbalance of aggregation and disaggregation between the glucose and diol groups of boronic-acid-modified CDs. Therefore, the fluorescent APBA-CDs for glucose were suitable to use as fluorescent sensors for glucose detection. Recently, in an impressive work, the boronic-acid-functionalized nitrogen-doped carbon dots were synthesized by Anjali Devi et al. (Figure 11).<sup>18</sup> The high pH conditions supported that the electron pair from the nitrogen atom of the amino group on dopamine (DA) successfully transferred to the surface defects of CDs. As a result, the CDs improved the fluorescence efficiency. The fluorescent probe had a slightly blue shift behavior when adding the high DA concentration (0–61 μM). From this result, the CDs exploited a good linear correlation ( $R^2 = 0.99498$ ) and an LOD of 89 pM. Consequently, the as-mentioned NCD-APBA was sufficiently utilized to investigate DA in the human serum (spiked) to obtain a good recovery percentage.

**3.4. Boronic-Acid-Modified Nanomaterials for Sensitive Glucose Sensors to Manage Diabetes.** Diabetes





**Figure 11.** Schematic diagram of the dopamine detection mechanism. Reproduced with permission from ref 18. Copyright 2017 Springer Nature.

mellitus, commonly known as diabetes, is one of the chronic diseases that, if not controlled properly, may cause serious health problems including eye, kidney, nerve, and heart disorders in our body. The high glucose levels in the blood are a quantification of glucose levels in physiological bloody fluid including blood, urine, etc., and they are essential to improving diabetes diagnosis and treatment. In 1962, Lelard C. Clark presented the first glucose enzyme electrode-like glucose sensor to determine glucose concentration in the management of diabetes.<sup>19</sup> As shown in Table S4 (Supporting Information), some of the important sensing performances influence the detection of glucose. The glucose-sensing-based CDs exhibited tunable photoluminescence, biocompatibility, photostability, low toxicity, high sensitivity to target analyses, and high quantum yield; therefore, the glucose concentration in the serum sample solution has been widely adopted.

Furthermore, functionalization of CDs with boronic acid enhanced the diagnostic ability of nonenzymatic glucose by covalent bonding formation with the monosaccharide compounds at normal conditions. Therefore, boronic acid is extensively applied for the improvement of fluorescent sensors, carbohydrate transporters, and color sensors. On fluorescent-based sensors, the frequencies of light are correlated with glucose amount because chemical attraction of the active fluorophores is glucose-concentration dependent.

More recently, the glucose sensor based on CDs with high quantum yield (46%) was improved to determine the concentration of glucose in samples of blood serum via an aggregation-induced emission (AIE) effect and monitored by a smartphone-based method as shown in Table S4 (Supporting Information). In the field of glucose sensors, the fluorescence emission of BCNP effectively improved with increasing concentration of glucose. BCNPs found a good linear correlation ( $R^2 = 0.9931$ ) in the  $32 \mu\text{M}$  to  $2 \text{ mM}$  concentration range with a LOD of  $8 \mu\text{M}$ . As reported above, the result of BCNPs for the glucose detection was better than the normal glucose amount in the blood sample (the level of glucose in normal blood is  $3.6\text{--}6.6 \text{ mM}$ ).


**3.4.1. Boronic-Acid-Modified Quantum Dots for Glucose Sensing.** In addition, QDs also used numerous applications for sensing and biosensing because they have high fluorescence. As an example, the phenylboronic-acid-modified CdTe/ZnTe/ZnS quantum dots (PBA-QDs) were studied for intracellular glucose probing by Wu et al.<sup>20</sup> The functionalized PBA on the

surface of QDs prepared linkers, which interacted with *cis*-diols to form a stable boronate compound and improved for continuous glucose sensing. At optimum conditions, the QDs performed linear corrections of PBA-QDs up to 0.9975 on a glucose concentration range of  $0.4 \text{ mM}$  to  $20.0 \text{ mM}$  and an LOD of about  $0.3 \text{ mM}$ . Therefore, physicochemical properties of QDs such as emission, wavelength, and collection efficiency also had an influence on the determination of glucose as a glucose probe in the living cells. In addition, the fluorescent QDs were prepared with inorganic semiconductor materials such as CdTe, CdSe, and ZnS, which can be developed in the two-component system for sensing transfers in the glucose aqueous solution. Thus, QDs were strongly performed as a dual-function probe with a two-component sensing system for the investigation of glucose and saccharide compounds simultaneously.

**3.4.2. Boronic-Acid-Modified Graphene Quantum Dots and Graphene Oxide for Glucose Sensing.** As shown in Table S4 (Supporting Information), the boron-doped graphene quantum dots (BGQDs) were reported from the boron-doped graphene (BG) using a hydrothermal approach for selective glucose sensing. The boronic acid sites on the BGQD surface facilitated their utility as a novel photoluminescence (PL) probe to label glucose sensors. It is proposed that due to the properties of boronic acid with glucose QDs created the stiff structure of BGQD glucose aggregates, inhibiting the intramolecular reaction, thus ensuring in an outstanding excessive boost inside the PL intensity. As previously explained, adding glucose into the BGQD solution (PBS solution at  $\text{pH} = 7.4$ ) leads to the aggregation-induced emission of the QDs according to the covalent binding among the boronic acid moieties. Therefore, QDs have efficiently improved the quenching of their fluorescence. From these results, the PL intensity of BGQDs was strongly increased with the glucose concentration range ( $0.1\text{--}10 \text{ mM}$ ) with a LOD up to  $0.03 \text{ mM}$ . On the other hand, synthesizing the biosensor as a glucose sensor with highly fluorescent quenching has also improved the beneficial nanoparticles by graphene-oxide-like carbon nano-materials.

**3.4.3. Boronic-Acid-Modified Carbon Dots for Glucose Sensing.** In comparison with the other carbon-based materials, there are few applications of carbon dots as nanosensors, even though they can easily be functionalized and immobilized with polymers for biochemical analysis. It was notable that Wang et al. reported the immobilization of fluorescent carbon dot microgels (NIPAM-AAm-VPBA) from three functional comonomers (*N*-isopropylacrylamide (NIPAM), acrylamide (AAM), and 4-vinylphenyl boronic acid (VPBA)), as well as fluorescent CDs (Figure 12).<sup>21</sup> The as-prepared glucose-imprinted poly-(NIPAM-AAm-VPBA)-CDs were able to be reversibly quenched, and the fluorescent gestures of the inserted CDs in the different glucose concentrations were recovered, which resulted in superior gesture reproducibility. The glucose-imprinted CD hybrid microgels also showed good sensitivity and selectivity for detecting glucose, which ranged between  $0 \text{ mM}$  and  $30 \text{ mM}$  at a  $\text{pH}$  value of  $7.4$ . In these conditions, the CDs exhibited nontoxic concentration ranging from  $25$  to  $100 \mu\text{g/mL}$ . The phenomenon of glucose-interconnected aggregation with carbon dots was applied to adjust the selective radiometric response to glucose and its effect on the quenching of carbon dot fluorescence. Interestingly, the intensity of carbon dot fluorescence significantly decreased with the rise of glucose concentration. Furthermore, the effect of  $\text{pH}$  was important to






**Figure 12.** Schematic synthesis representation of the glucose-imprinted poly(NIPAM-AAm-VPBA)-CD hybrid microgels with certain binding sites on glucose for truly sensitive and selective glucose detection, which was based on the one-step free radical precipitation polymerization in water. Reproduced with permission from ref 21. Copyright 2015 American Chemical Society.

determine the stability of PL through the protonation and deprotonation of the molecules on the carbon dots. Therefore, the intensity of carbon dot fluorescence demonstrated a great dynamic response to the various glucose concentration ranges (1–100 mM) with linear coefficient  $R^2 = 0.996$  (Table S4 (Supporting Information)).

For another case, Das's group published the preparation of CDs from sulfated polysaccharides *k*-carrageenan and phenylboronic acid for glucose determination (nonenzymatic monosaccharide) and their antidiabetes drug release properties via one-step hydrothermal treatment (Figure 13a).<sup>22</sup> The quenching capability of the boron, sulfur-doped carbon dots (BSC-dots) on above the pH conditions (maximum is pH 7.5) formed the boronate complex due to their proton donation reaction. The aggregation of BSC dots with glucose molecules was served through electrostatic interactions at pH 7–8.




**Figure 13.** (a) Synthesis method of BSC dots. (b) Proposed representation process of BSC dots with the glucose molecule. Reproduced with permission from ref 22. Copyright 2019 Elsevier B.V.

Therefore, pH 7.5 was selected for the proposed mechanism of combining BSC dots with the glucose (Figure 13b). The CDs can be bound with various glucose concentrations (0–210  $\mu\text{M}$ ) on the blood sample. The good linear response had a concentration range from 0 to 210  $\mu\text{M}$  ( $R^2 = 0.987$ ) with an LOD of 1.7  $\mu\text{M}$ . They suggested that the BSC dots were further applied as antidiabetes chemosensors because of their excellent biocompatibility.

**3.5. Boronic-Acid-Modified Nanomaterials for Antiviral Inhibitor.** The human immunodeficiency virus (HIV) is a global pandemic virus that causes acquired immunodeficiency syndrome (AIDS). Currently, HIV-1 infection can be efficiently instructed using multiple antiviral inhibitions, which are designated as a combination of antiretroviral therapy (cART) and a new ART drug. However, they have only limited or transient clinical benefits and are still highly desirable due to their major side effects (e.g., long-term toxicity) along with the rapidly developed virus drug resistance. Up to now, many researchers have still discovered no possible diagnostic interaction between the human immunodeficiency virus (HIV) and various drug materials. Particularly, the boron-containing materials are further attracting considerable interest for biomedical and biological applications. Previous authors have reviewed the new biological activity of drug design for pharmaceutical drugs using the boron element.<sup>23</sup> We have summarized the boron-containing materials including an organic compound, polymer, and nanoparticles for antiviral inhibition in Table S5 (Supporting Information) and boromycin that has an inhibitory effect, which highly blocks the replication step of cultured strain on the HIV life cycle. Boronic acid, as mentioned before, initiates essential binding with *cis*-diols for saccharide identification. There are as many hydroxyl moieties on the organic macromolecule as on the T cell surface. These phenomena open alternative ways for inhibition of HIV and antiretroviral infection using boronic-acid-motivated materials, including CDs. It was well noted that nanomaterials have interesting aspects for materials as small as a virus, the aspect ratio being closely related with the size of the nanoparticle that is smaller than that of the virus and thus easily disturbing the virus metabolism. Moreover, Table S5 (Supporting Information) shows that most applications of boronic acid nanomaterials on HIV therapy will relate to diol functional groups on gp120 overexpressed on the HIV surface. This shows the importance of boronic acid moiety applications on HIV therapy.

**3.5.1. HIV-1 Barrier.** One of the initial strains of HIV transmission in heterosexual sex is through moving of the biological fluids (from the seminal fluid to the vaginal fluid). Hence, the development of materials used to prevent the transition of the virions from the semen to the vaginal cell wall becomes a crucial aspect, which also depends upon the pH of the biofluids. The pH range of vaginal fluid is 4 to 5 which can be changed due to the kind of buffer, volume of buffer, the basicity of the pH, and semen capacity. Nevertheless, efficient transmission of HIV virions is through an impermeable gel type to the cell as well as through associated cells of virions with the neutral pH of seminal fluid. For example, Mahalingam et al. constructed a polymer similar to mucin with PBA (phenylboronic acid) and salicylghdroxamic acid (SHA), each separately polymerized with a 2-hydroxypropylmethacrylamide (PHPMA).<sup>24</sup> The interaction of the phenylboronic acid (PBA) and salicylghdroxamic acid (SHA) has exhibited a weak



**Figure 14.** (I) An applicator (a) is formed for applying a weakly cross-linked viscoelastic fluid between the two-polymer solution (b). (II) The gel forms as a barrier in the middle of the vaginal mucosa and an environment. (III) The gel includes the cross-links joining the PBA (blue) and SHA (yellow) of the two polymers (d) and the bioadhesive interaction between PBA and diol moieties (e) within cervical mucus (c) and on the epithelial surface. (IV) At neutral pH, the densely cross-linked elastic network of hydrogel inhibited the virion diffusion (g) to the vaginal mucosa. (V) The pH-dependent conjugation between free and boronate-cross-linked hydrogel with salicylgydroxamic acid. Reproduced with permission from ref 24. Copyright 2011 Elsevier Ltd.

interaction under acidic pH conditions; it even has a larger combination constant at neutral pH conditions (Figure 14).

The viscoelastic nature of the covalently cross-linked PBA-SHA could be connected with mucous that prohibits the transfer of virions into cells in response to pH conditions. The benzoborazole moieties containing polymer can be combined with the group of mannoses on gp120, which could delay the HIV-1 activity before interacting with the CD4+ receptor in the cell (Figure S4). Due to the above-mentioned results, these polymers disturbed the transmission of HIV-1 entry into the cell.

**3.5.2. HIV-1 Inhibition.** The ongoing research on polymer modification with boronic acid has led some researchers to make improvements by modifying CDs with boronic acid and further applying them for HIV detection. As an example, Fahmi et al. have focused the antiviral drugs on the gp120 target entry inhibition concept using boronic-acid-modified carbon dots.<sup>25</sup> Indeed, the initial step of the life cycle of HIV virions was the gp120 interaction with the CD4 receptor on the target cell, gp120 mostly contains oligosaccharides and mannose sites with many hydroxyl groups. In this study, the noble CDs were prepared from citric acid (CA) as a carbon source and 4-carboxy-3-chlorobenzene boronic acid (CBBA) as a specific targeting agent for inhibition of HIV-1 entry. For experimental work, the inhibition ability of CBBA-CDs was examined by the infection in the cell-to-cell process, and the production of syncytia numbers was counted after incubation for 24 h using the cultured MT4/HIV-1 and MOLT-4 cells. After incubation with 300  $\mu\text{g}/\text{mL}$  concentration of CBBA-CDs, the formation of syncytia was effectively prevented due to the combination with gp120 on the virus surface. According to the results, the high concentration of CBBA-CDs (75–600  $\mu\text{g}/\text{mL}$ ) more significantly inhibited the HIV-1 entry than the low concentration (4.69–37.5  $\mu\text{g}/\text{mL}$ ). Therefore, Fahmi's group found that the CDs successfully inhibited the connection of virions with MOLT-4 cells and blocked the virion activities. The as-reported GQDs could be developed to envision HIV DNA's dynamic invasions into the HeLa cells. Particularly, boron and nitrogen doping on GQDs supported the conjugation of this nanoma-

terial with HIV's DNA. Interestingly, the platform of sense usually coordinates a fluorophore and also a quencher that is attached by a single-stranded DNA probe molecule using fluorescence resonance energy transfer (FRET). Creating noncovalent bonds between probes and target HIV DNA is also important to reach high affinity and encourage the sensing platform. From the discussion above, the active boronic acid moiety strongly blocked the initial step of viral infection by cyclic ester formation through both chemical interaction and physical interaction. Also, the boromycin compounds have anti-HIV activity, which depends on the effect of the maturity stage for HIV replication. Thus, these biocompatible boron-modified nanomaterials were used for long interaction with glycoprotein and polysaccharide compounds and their intracellular distribution on the living cell membrane. On the other hand, most of the CDs exhibited fluorescent ability in the short-wavelength region (blue or green).<sup>13</sup> However, a study revealed that the red fluorescence of boronic-acid-modified CDs had an emission range of 620 nm, which could be deeply penetrated on the cell surface through the endocytic pathways with SA groups.<sup>12</sup>

## 4. CONCLUSION

In the research field of nanoparticles, CDs (CQDs, GQDs, PDs) have achieved tremendous importance in the last 10 years owing to their effectiveness, good biosafety, optical properties, and excellent biocompatibility. Herein, we have highlighted the boronic-acid-functionalized CDs in terms of their synthesis, properties, and biomedical applications. Although diverse synthetic methods have been demonstrated for CDs, one of the main synthesis processes for carbon dots is the hydrothermal/solvothermal method due to their low cost, stable luminescence, high QY, and ease of modification with starting materials (Table S1). For instance, the red emitted CDs (QY: 64.95%) are efficiently used for in vivo imaging. However, the QY of CDs depends on the solvent used. Additionally, the red-emission CDs were effectively used for selective determination of  $\text{Fe}^{3+}$ , sialic acid, cancer therapy, and bioimaging, respectively. Therefore, the functionalization/passivation of CDs with boron doping atoms was a crucial aspect not only to enhance desired

optical properties but also to drive the material specific to its target. As Table S3 describes, the boronic-acid-modified CDs have been well controlled with the fluorescence at blue, green, yellow, and red wavelengths. Particularly, the multivalent interaction between boronic acid and *cis*-diol groups, producing reversible molecular assembly reactions on the biomolecule target, becomes the most important part of bioapplications for boronic-acid-containing nanomaterials. Therefore, the boronic-acid-modified CDs well demonstrated various potential in bioimaging, sensing, drug delivery, and inhibition.

## 5. CHALLENGES AND PERSPECTIVES

In this mini-review, boron derivative compounds including the synthesis of boronic-acid-modified carbon dots (GQDs, CQDs, PDs) and their properties were explained. The improvement of CDs for application in biomedical fields has been extensively updated within the research realm. Nevertheless, further challenging research still needs to be done for clarification. Tremendous efforts by researchers worldwide on improving the synthesis, mechanism, and performance of CDs are being devoted to these nanomaterials as promising luminescent materials, using diverse methods and sometimes inventing the selectivity and drug delivery inhibition that is still challenging. The limitations on larger size distribution, poor control of uniform size, and complex and unclear photoluminescence of prepared CDs are also important aspects for improvement.

In the case of boronic-acid-modified CDs, there are still many challenges that need to be solved, including toxicity, QY enhancement, multiinteraction system, surface passivation, and functionalization of the synthesis process that needs to be efficiently developed for the photostability and biocompatibility of CDs. Therefore, the advantages of the synthesis process should be studied more to achieve high QY, small particle size, and excellent biocompatibility. Furthermore, new boronic-acid-modified materials are formed by imprinting the multi-interaction of glucose moieties in this application area. In this mini-review, despite the above-reported challenges, the boronic-acid-modified nanomaterials have become excellent promising research materials for the future for various biological applications such as bioimaging, biosensing, and antiretroviral therapy. On the other hand, boronic-acid-modified carbon dots could inhibit viral HIV infection due to the chemical interaction effect. Also, the host genomic factors of the Covid-19 (SARS-CoV-2) virus are similar to the construction of the HIV-1 virus. Based on this phenomenon, research on boronic-acid-modified nanomaterials can be expanded to modern diseases like SARS-CoV-2, MERS-CoV, and other virus-based diseases coming in the future. The combination of experimental and theoretical studies will provide more worthy information and interesting aspects. We hope the information from this mini-review can provide guidance to the further use of boronic-acid-modified nanoparticles for many applications.

## ■ ASSOCIATED CONTENT

### SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.1c01352>.

Several data such as advantages and disadvantages of different synthesis methods (Table S1); the hydrothermal method for boron-modified carbon dots (Table S2); boronic-acid-modified CDs for cell imaging and cancer cell treatment (Table S3); sensing performance

for glucose detection (Table S4); the summarization of the boron-containing materials for antiviral inhibition (Table S5); images of fluorescence microscopy and bright-field transmission of HeLa cells (Figure S1); confocal fluorescent images of HeLa cells without BCQDs and incubated with BCQDs (Figure S2); confocal laser scanning bright-field and fluorescence images of cells (HeLa, B16F10, NIH3T3) (Figure S3) (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

Mochamad Zakki Fahmi – Department of Chemistry and Supramodification Nano-Micro Engineering Research Group, Airlangga University, Surabaya 60115, Indonesia; [orcid.org/0000-0001-5430-9992](https://orcid.org/0000-0001-5430-9992); Email: [m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)

### Authors

Yu-Yu Aung – Department of Chemistry, Airlangga University, Surabaya 60115, Indonesia; [orcid.org/0000-0002-2169-4983](https://orcid.org/0000-0002-2169-4983)

Alfinda Novi Kristanti – Department of Chemistry, Airlangga University, Surabaya 60115, Indonesia

Hwei Voon Lee – Nanotechnology & Catalysis Research Centre (NANOCAT), Institute of Advance Studies, University of Malaya, 50603 Kuala Lumpur, Malaysia; [orcid.org/0000-0002-2997-5675](https://orcid.org/0000-0002-2997-5675)

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acsomega.1c01352>

### Author Contributions

Yu Yu Aung studied the literature; Alfinda Novi Kristanti proofread; Hwei Voon Lee proofread; and Mochamad Zakki Fahmi proofread, studied the literature, and was editor of the manuscript.

### Notes

The authors declare no competing financial interest.

### Biographies



Yu Yu Aung received her master's degree (2009) in chemistry at Myitkyina University, Myanmar. Presently, she is studying as a Ph.D. researcher under the supervision of Associate Professor Dr. Mochamad Zakki Fahmi and Associate Professor Dr. Alfinda Novi Kristanti at Universitas Airlangga, Indonesia. Her research interest is based on boronic acid modified carbon dots for HIV-1 inhibition and cancer cell staining.





Alfinda Novi Kristanti obtained her Doctorate in Organic Chemistry from Universite de Haute-Alsace, France, in 1997, under the supervision of Prof. Bernard Muckensturm. At this time, she is an associate professor at the Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Indonesia. Her research interests are on Natural Product Chemistry and Organic Synthesis.



Dr. Hwei Voon Lee is a senior lecturer at the Nanotechnology and Catalysis Research Center (NANOCAT), University of Malaya, Malaysia. She received her Ph.D. in Catalysis (2013) and B.Sc. (Hons) in Industrial Chemistry (2008) from the Universiti Putra Malaysia. Her major research interests are energy and fuels (biodiesel, renewable diesel, biofuels), biomass conversion technology (catalytic conversion of biomass), oleochemical technology (methyl ester, polyol ester), catalysis (heterogeneous catalyst, mixed metal oxides, acid-base catalyst), and nanomaterials (biomass-derived nanocrystalline cellulose and application).



Mochamad Zakki Fahmi got his Ph.D. in Chemical Engineering in 2014 from the National Taiwan University of Science and Technology. Currently, he works as an Associate Professor at the Department of

Chemistry Universitas Airlangga. His focus is on the study of medical purposed nanomaterials used mainly for theranostics of cancer and HIV.

## ACKNOWLEDGMENTS

The authors gratefully thank the MANDAT research funding program of Airlangga University (Contract No. 463/UN3.15/PT/2021) for partial financial support under the Ministry of Science, Technology and Higher Education, Republic of Indonesia.

## ABBREVIATIONS

CDs, carbon dots; QDs, quantum dots; GQDs, graphene quantum dots; CQDs, carbon quantum dots; PDS, polymer dots; GO, graphene oxide; HIV, human immunodeficiency virus; pH, power of hydrogen; PL, photoluminescent; gp 120, glycoprotein 120; QY, quantum yield; ORR, oxygen reduction reaction; BGQDs, boron-doped graphene quantum dots; BCQDs, boron-doped carbon quantum dots; LOD, limit of detection; LOQ, limit of quantification; DA, dopamine; rBA-CDs, reactive boronic-acid-functionalized carbon dots; N-B-CQDs, boron and nitrogen codoped carbon dots; PCQDs, 3-aminophenylboronic-acid-functionalized graphitic carbon nitride quantum dots; SA, sialic acid; BNS-CDs, boron, nitrogen, sulfur-codoped carbon dots; g-CNQDs/3APBA, aminoboronic-acid-functionalized graphitic carbon nitride quantum dots; B-CNPs, boron-doped carbon nanoparticles; MR, magnetic resonance; RCDs1s, photosensitizer(riboflavin)-tailed surface-functionalized carbon dots; ROS, reactive oxygen species; H16F10, melanoma cell; NIH3T3, noncancerous cell; DDS, drug delivery system; Dox, doxorubicin; NPs, nanoparticles; CCM, magnetic nanoparticles; DCCM, doxorubicin-carbon combined magnetic nanoparticles; CLSM, confocal laser scanning microscope; PB-AuNCs, phenylboronic acid template gold nanoclusters; CLO<sup>-</sup>, hypochlorite; ARS, alizarin red S; B-MoS<sub>2</sub>QDs, boronic-acid-functionalized molybdenum disulfide quantum dots; FRET, fluorescent energy transfer; IFE, inner filter effect; RLS, resonance light scattering; APBA-GQDs, boronic-acid-functionalized graphene quantum dots; DAPEG, diacrylate polyethylene glycol; AIE, aggregation-induced emission; BCNP, boronic-acid-doped carbon nanoparticles; PBA-QDs, phenylboronic-acid-functionalized graphitic carbon nitride quantum dots; HS, horse serum; rGO-PBA, phenylboronic acid functionalized with reduced graphene oxide; NIPAM-AAm-VPBA, immobilization fluorescent carbon dot microgel; BSC-dots, boron, sulfur-doped carbon dots; (VPBA-AAm)-CDs, carbon-dot-immobilized hybride microgel poly; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HSV-1, herpes simplex type 1

## REFERENCES

- (1) Semeniuk, M.; Yi, Z.; Poursorkhabi, V.; Tjong, J.; Jaffer, S.; Lu, Z.-H.; Sain, M. Future perspectives and review on organic carbon dots in electronic applications. *ACS Nano* **2019**, *13* (6), 6224–6255.
- (2) Cambre, J. N.; Sumerlin, B. S. Biomedical applications of boronic acid polymers. *Polymer* **2011**, *52* (21), 4631–4643.
- (3) Hall, D. G. *Boronic acids: preparation, applications in organic synthesis and medicine*; John Wiley & Sons: 2006.
- (4) Bull, S. D.; Davidson, M. G.; Van den Elsen, J. M.; Fossey, J. S.; Jenkins, A. T. A.; Jiang, Y.-B.; Kubo, Y.; Marken, F.; Sakurai, K.; Zhao, J. Exploiting the reversible covalent bonding of boronic acids: recognition, sensing, and assembly. *Acc. Chem. Res.* **2013**, *46* (2), 312–326.



- (5) Brooks, W. L. A.; Sumerlin, B. S. Synthesis and applications of boronic acid-containing polymers: from materials to medicine. *Chem. Rev.* **2016**, *116* (3), 1375–1397.
- (6) Tao, S.; Lu, S.; Geng, Y.; Zhu, S.; Redfern, S. A.; Song, Y.; Feng, T.; Xu, W.; Yang, B. Design of metal-free polymer carbon dots: a new class of room-temperature phosphorescent materials. *Angew. Chem., Int. Ed.* **2018**, *57* (9), 2393–2398.
- (7) Wibrianto, A.; Khairunisa, S. Q.; Sakti, S. C.; Ni'mah, Y. L.; Purwanto, B.; Fahmi, M. Z. Comparison of the effects of synthesis methods of B, N, S, and P-doped carbon dots with high photoluminescence properties on HeLa tumor cells. *RSC Adv.* **2021**, *11* (2), 1098–1108.
- (8) Shen, C.; Wang, J.; Cao, Y.; Lu, Y. Facile access to B-doped solid-state fluorescent carbon dots toward light emitting devices and cell imaging agents. *J. Mater. Chem. C* **2015**, *3* (26), 6668–6675.
- (9) Xu, S.; Che, S.; Ma, P.; Zhang, F.; Xu, L.; Liu, X.; Wang, X.; Song, D.; Sun, Y. One-step fabrication of boronic-acid-functionalized carbon dots for the detection of sialic acid. *Talanta* **2019**, *197*, 548–552.
- (10) Ye, Q.; Yan, F.; Kong, D.; Zhang, J.; Zhou, X.; Xu, J.; Chen, L. Constructing a fluorescent probe for specific detection of catechol based on 4-carboxyphenylboronic acid-functionalized carbon dots. *Sens. Actuators, B* **2017**, *250*, 712–720.
- (11) Jiang, G.; Jiang, T.; Li, X.; Wei, Z.; Du, X.; Wang, X. Boronic acid functionalized N-doped carbon quantum dots as fluorescent probe for selective and sensitive glucose determination. *Mater. Res. Express* **2014**, *1* (2), 025708.
- (12) Liu, A.; Peng, S.; Soo, J. C.; Kuang, M.; Chen, P.; Duan, H. Quantum dots with phenylboronic acid tags for specific labeling of sialic acids on living cells. *Anal. Chem.* **2011**, *83* (3), 1124–1130.
- (13) Zhang, M.; Wang, Q.; Xu, Y.; Guo, L.; Lai, Z.; Li, Z. Graphitic carbon nitride quantum dots as analytical probe for viewing sialic acid on the surface of cells and tissues. *Anal. Chim. Acta* **2020**, *1095*, 204–211.
- (14) Thi Ngo, Y.-L.; Chung, J. S.; Hur, S. H. Aminoboronic acid-functionalized graphitic carbon nitride quantum dots for the photoluminescence multi-chemical sensing probe. *Dyes Pigm.* **2019**, *168*, 180–188.
- (15) Zhao, X.; Dong, L.; Ming, Y.; Wang, M.; Lu, Z.; Xu, Y.; Li, H. A magnetofluorescent boron-doped carbon dots as a metal-free bimodal probe. *Talanta* **2019**, *200*, 9–14.
- (16) Fahmi, M. Z.; Chen, J. K.; Huang, C. C.; Ling, Y. C.; Chang, J. Y. Phenylboronic acid-modified magnetic nanoparticles as a platform for carbon dot conjugation and doxorubicin delivery. *J. Mater. Chem. B* **2015**, *3* (27), 5532–5543.
- (17) Zou, W. S.; Ye, C. H.; Wang, Y. Q.; Li, W. H.; Huang, X. H. A hybrid ratiometric probe for glucose detection based on synchronous responses to fluorescence quenching and resonance light scattering enhancement of boronic acid functionalized carbon dots. *Sens. Actuators, B* **2018**, *271*, 54–63.
- (18) Anjali Devi, J. S.; Anulekshmi, A. H.; Salini, S.; Aparna, R. S.; George, S. Boronic acid functionalized nitrogen doped carbon dots for fluorescent turn-on detection of dopamine. *Microchim. Acta* **2017**, *184* (10), 4081–4090.
- (19) Clark, L. C.; Lyons, C. Electrode Systems for Continuous Monitoring in Cardiovascular Surgery. *Ann. N. Y. Acad. Sci.* **1962**, *102* (1), 29–45.
- (20) Wu, W.; Zhou, T.; Berliner, A.; Banerjee, P.; Zhou, S. Glucose-mediated assembly of phenylboronic acid modified CdTe/ZnTe/ZnS quantum dots for intracellular glucose probing. *Angew. Chem., Int. Ed.* **2010**, *49* (37), 6554–6558.
- (21) Wang, H.; Yi, J.; Velado, D.; Yu, Y.; Zhou, S. Immobilization of Carbon Dots in Molecularly Imprinted Microgels for Optical Sensing of Glucose at Physiological pH. *ACS Appl. Mater. Interfaces* **2015**, *7* (29), 15735–15745.
- (22) Das, P.; Maity, P. P.; Ganguly, S.; Ghosh, S.; Baral, J.; Bose, M.; Choudhary, S.; Gangopadhyay, S.; Dhara, S.; Das, A. K. Biocompatible carbon dots derived from  $\kappa$ -carrageenan and phenyl boronic acid for dual modality sensing platform of sugar and its anti-diabetic drug release behavior. *Int. J. Biol. Macromol.* **2019**, *132*, 316–329.
- (23) Ban, H. S.; Nakamura, H. Boron-based drug design. *Chem. Rec.* **2015**, *15* (3), 616–635.
- (24) Mahalingam, A.; Jay, J. I.; Langheinrich, K.; Shukair, S.; McRaven, M. D.; Rohan, L. C.; Herold, B. C.; Hope, T. J.; Kiser, P. F. Inhibition of the transport of HIV in vitro using a pH-responsive synthetic mucin-like polymer system. *Biomaterials* **2011**, *32* (33), 8343–8355.
- (25) Fahmi, M. Z.; Sukmayani, W.; Khairunisa, S. Q.; Witaningrum, A. M.; Indriati, D. W.; Matondang, M. Q. Y.; Chang, J. Y.; Kotaki, T.; Kameoka, M. Design of boronic acid-attributed carbon dots on inhibits HIV-1 entry. *RSC Adv.* **2016**, *6* (95), 92996–93002.



[Open Access](#)  
[Submission & Review](#)  
[About the Journal](#)

## Editors & Editorial Board

### Editors-in-Chief

#### **Krishna N. Ganesh**

Indian Institute of Science Education &  
Research  
India  
E-mail: [ganesh-office@omega.acs.org](mailto:ganesh-office@omega.acs.org)

#### **Deqing Zhang**

Institute of Chemistry, Chinese Academy of  
Sciences  
China  
E-mail: [zhang-office@omega.acs.org](mailto:zhang-office@omega.acs.org)

### Current Issue Editorial Masthead

[View the Masthead in Current Issue](#)

### Senior Editors

#### **Sarbajit Banerjee**

Texas A&M University  
United States  
E-mail: [Banerjee-office@omega.acs.org](mailto:Banerjee-office@omega.acs.org)

#### **Frank H. Quina**

Universidade de São Paulo  
Brazil  
E-mail: [quina-office@omega.acs.org](mailto:quina-office@omega.acs.org)

### Associate Editors

#### **Esra Çapanoğlu Güven**

Istanbul Technical University  
Turkey  
E-mail: [Capanoglu-office@omega.acs.org](mailto:Capanoglu-office@omega.acs.org)

#### **Dipankar Chatterji**

Indian Institute of Science  
India  
E-mail: [chatterji-office@omega.acs.org](mailto:chatterji-office@omega.acs.org)

Email: [guo-office@omega.acs.org](mailto:guo-office@omega.acs.org)

### **Johan Hofkens**

Katholieke Universiteit Leuven  
Belgium  
E-mail: [hofkens-office@omega.acs.org](mailto:hofkens-office@omega.acs.org)

### **Jesús Jiménez-Barbero**

CIC bioGUNE  
Spain  
E-mail: [jimenez-barbero-office@omega.acs.org](mailto:jimenez-barbero-office@omega.acs.org)

### **Jeehiun K. Lee**

Rutgers University  
United States  
E-mail: [lee-office@omega.acs.org](mailto:lee-office@omega.acs.org)

### **Mohamed Mahmoud**

King Fahd University of Petroleum & Minerals  
Saudi Arabia  
E-mail: [mahmoud-office@omega.acs.org](mailto:mahmoud-office@omega.acs.org)

## **Senior Managing Editor**

### **Dinesh Soares**

E-mail: [managing.editor@omega.acs.org](mailto:managing.editor@omega.acs.org)

## **Editorial Advisory Board**

### **Ayyappanpillai Ajayaghosh**

CSIR–National Institute for Interdisciplinary  
Science and Technology  
India

### **Nageh Allam**

The American University in Cairo  
Egypt

### **Markus Antonietti**

Max Planck Institute of Colloids and Interfaces  
Germany

Email: [ogoshi-office@omega.acs.org](mailto:ogoshi-office@omega.acs.org)

### **Luisa Torsi**

Università Degli Studi Di Bari  
Italy  
E-mail: [torsi-office@omega.acs.org](mailto:torsi-office@omega.acs.org)

### **Adelina Voutchkova-Kostal**

George Washington University  
United States  
E-mail: [voutchkova-kostal-office@omega.acs.org](mailto:voutchkova-kostal-office@omega.acs.org)

### **Jing-Lin Zuo**

Nanjing University  
China  
E-mail: [zuo-office@omega.acs.org](mailto:zuo-office@omega.acs.org)

### **Jürgen Bajorath**

University of Bonn  
Germany

### **Damià Barceló**

Catalan Institute for Water Research (ICRA)  
Spain

### **Suddhasatwa Basu**

Indian Institute of Technology Delhi  
India

**Parbati Biswas**

University of Delhi  
India

**Maria Valnice Boldrin Zanoni**

Universidade Estadual Paulista  
Brazil

**Sami Boufi**

University of Sfax  
Tunisia

**Luis M. Campos**

Columbia University  
United States

**Nagasuma Chandra**

Indian Institute of Science  
India

**Vadapalli Chandrasekhar**

Indian Institute of Technology Kanpur  
India

**Yu-Ju Chen**

Academia Sinica  
Taiwan

**Cathleen Crudden**

Queen's University  
Canada

**Swagata Dasgupta**

Indian Institute of Technology Kharagpur  
India

**Jyotirmayee Dash**

Indian Association for the Cultivation of  
Science  
India

**Beatriz Garcia de la Torre**

University of KwaZulu-Natal  
South Africa

**Takayuki Doi**

Tohoku University  
Japan

**Eno Ebenso**

North-West University  
South Africa

**Qing-Hua Fan**

Institute of Chemistry, Chinese Academy of  
Sciences  
China

**Rute A. S. Ferreira**

University of Aveiro  
Portugal

**Mary Garson**

University of Queensland  
Australia

**Mónica C. Gonzalez**

Universidad Nacional de La Plata  
Argentina

**Concepción González-Bello**

Universidade de Santiago de Compostela  
Spain

**Murray R. Gray**

University of Alberta  
Canada

**Xuefeng Guo**

Peking University  
China

**Jennifer M. Heemstra**

Emory University  
United States

**Thomas Hellweg**

Bielefeld University  
Germany



**Albena Ivanisevic**

North Carolina State University  
United States

**Rebecca A. Jockusch**

University of Toronto  
Canada

**Katrina A. Jolliffe**

The University of Sydney  
Australia

**Beatriz H. Juárez**

Universidad Autónoma de Madrid  
Spain

**Tanja Junkers**

Monash University  
Australia

**Lynn Kamerlin**

Uppsala University  
Sweden

**Niveen Khashab**

King Abdullah University of Science and  
Technology (KAUST)  
Saudi Arabia

**Katalin E. Kövér**

University of Debrecen  
Hungary

**Elizabeth Krenske**

The University of Queensland  
Australia

**Yamuna Krishnan**

University of Chicago  
United States

India

**Hye Jin Lee**

Kyungpook National University  
Republic of Korea

**Angel Leiva Campusano**

Pontificia Universidad Católica de Chile  
Chile

**Michal Leskes**

Weizmann Institute of Science  
Israel

**Zhen Li**

Wuhan University  
China

**Darren Lipomi**

University of California, San Diego  
United States

**Lei Liu**

Tsinghua University  
China

**Watson Loh**

UNICAMP Universidade Estadual de Campinas  
Brazil

**Katja Loos**

University of Groningen  
Netherlands

**Norberto Peporine Lopes**

University of São Paulo  
Brazil

**Lanqun Mao**

Institute of Chemistry, Chinese Academy of  
Sciences  
China

**Manjusri Misra**

University of Guelph  
Canada

**Maria Cruz Moreno Bondi**

Complutense University of Madrid  
Spain

**Claudio J.A. Mota**

Federal University of Rio de Janeiro  
Brazil

**Govindasamy Mugesh**

Indian Institute of Science  
India

**Daniel H. Murgida**

University of Buenos Aires and CONICET  
Argentina

**Maria Nowakowska**

Jagiellonian University  
Poland

**Cátia Ornelas**

UNICAMP Universidade Estadual de Campinas  
Brazil

**Takeaki Ozawa**

The University of Tokyo  
Japan

**Sofia I. Pascu**

University of Bath  
United Kingdom

**Suprakas Sinha Ray**

Council for Scientific and Industrial Research  
South Africa

**Coralia Osorio Roa**

Universidad Nacional de Colombia  
Colombia

**Paolo Samori**

University of Strasbourg & The National Center  
for Scientific Research  
France

**Clément Sanchez**

Collège de France  
France

**Anubhav Saxena**

Pidilite Industries Limited  
India

**Ester Segal**

Technion – Israel Institute of Technology  
Israel

**Tamar Seideman**

Northwestern University  
United States

**Alba Silipo**

Università degli Studi di Napoli "Federico II"  
Italy

**Svetlana Simova**

Bulgarian Academy of Sciences  
Bulgaria

**Jayant Singh**

Indian Institute of Technology Kanpur  
India

**Ekaterina V. Skorb**

ITMO University  
Russian Federation

**Miquel Solà**

Universitat de Girona  
Spain

**Christopher Southan**

TW2Informatics Ltd  
United Kingdom

**Sabine Szunerits**

Université de Lille  
France

**Kazuo Takimiya**

RIKEN  
Japan

**Keiichi Tomishige**

Tohoku University  
Japan

**Ilja K. Voets**

Eindhoven University of Technology  
Netherlands

**Nicolas Vogel**

Friedrich-Alexander University Erlangen-  
Nürnberg  
Germany

**Li-Jun Wan**

Institute of Chemistry Chinese Academy of  
Sciences  
China

**Yilin Wang**

Institute of Chemistry Chinese Academy of  
Sciences  
China

**Shu Wang**

Institute of Chemistry Chinese Academy of  
Sciences  
China

**Davita L. Watkins**

University of Mississippi  
United States

**Robert S. Weber**

Pacific Northwest National Laboratory  
United States

**Emily A. Weiss**

Northwestern University  
United States

**Luisa Whittaker-Brooks**

University of Utah  
United States

**Nicolas Winssinger**

University of Geneva  
Switzerland

**Jishan Wu**

National University of Singapore  
Singapore

**Li-Zhu Wu**

Chinese Academy of Sciences  
China

**Matthias Wüst**

University of Bonn  
Germany

**Zhenfeng Xi**

Peking University  
China

**Vivian W. W. Yam**

The University of Hong Kong  
China

**Juyoung Yoon**

Ewha Womans University  
Republic of Korea

**Hua Zhang**

City University of Hong Kong  
China

**Xi Zhang**

Tsinghua University  
China















  
Connecting Research  
and Researchers



 **ACS Publications**  
Most Trusted. Most Cited. Most Read.

1155 Sixteenth Street N.W.  
Washington, DC 20036  
Copyright © 2021  
American Chemical Society

## About

[About ACS Publications](#)  
[ACS & Open Access](#)  
[ACS Membership](#)

## Resources and Information

[Journals A-Z](#)  
[Books and Reference](#)  
[Advertising Media Kit](#)  
[Institutional Sales](#)  
[ACS Publishing Center](#)  
[Privacy Policy](#)  
[Terms of Use](#)

## Support & Contact

[Help](#)  
[Live Chat](#)  
[FAQ](#)

**Connect with ACS Publications**





Ads by Google


Stop seeing this ad

Why this ad? ⓘ

# ACS Omega

**COUNTRY**

United States




**SUBJECT AREA AND CATEGORY**

Chemical Engineering  
 ↳ Chemical Engineering (miscellaneous)  
 Chemistry  
 ↳ Chemistry (miscellaneous)

**PUBLISHER**

American Chemical Society



**H-INDEX**

**40**

**PUBLICATION TYPE**

Journals

**ISSN**

24701343

**COVERAGE**

2016-2020

**INFORMATION**

[Homepage](#)  
[How to publish in this journal](#)  
[Ganesh-office@omega.acs.org](mailto:Ganesh-office@omega.acs.org)



**Kembali Sekolah Bersama MSI**



←

Ads by Google

Stop seeing this ad

Why this ad? ⓘ

## SCOPE

ACS Omega is an open-access global publication for scientific articles that describe new findings in chemistry and interfacing areas of science, without any perceived evaluation of immediate impact. ACS Omega is a global open-access journal for the publication of scientific articles that describe new findings in chemistry and interfacing areas of science, without any perceived evaluation of immediate impact. Articles in ACS Omega should advance the frontiers of science through original ideas, even if the full significance is not known. ACS Omega disseminates this knowledge globally and quickly by immediately making all accepted articles open access in perpetuity. Papers published in ACS Omega are therefore available to a much wider readership that includes industry, policy institutions, the media and the general public, in addition to the traditional academic sector.

🗨️ Join the conversation about this journal

---

## English Grammar Checker

Check your grammar, spelling, and punctuation instantly with Gramr

Grammarly

[Learn More](#)

🔼 Quartiles





Stop seeing this ad

Why this ad? ⓘ

### One App for Team Collaboration

Collaborate easily no matter how big the meeting. Invite up to 500 p  
Learn More.

Avaya Spaces

Sign

#### FIND SIMILAR JOURNALS ?

1  
**Frontiers in Chemistry**

CHE

**94%**

similarity

2  
**RSC Advances**

GBR

**88%**

similarity

3  
**Progress in Chemistry**

CHN

**81%**






similarity

4  
**New Journal of C**

GBR

**79%**



similarity




## Ads by Google

Stop seeing this ad

Why this ad? ⓘ



● Cited documents ● Uncited documents



ACS Omega

Q1

Chemical Engineering (miscellaneous) best quartile

SJR 2020

0.78

powered by scimagojr.com

← Show this widget in your own website


Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" data-bbox="612 353 758 368">
```

 SCImago Graphica

Explore, visually communicate and make sense of data with our **new free tool**.

Get it



Metrics based on Scopus® data as of April 2021

R

Rafael 5 months ago

[Stop seeing this ad](#)[Why this ad?](#) ⓘ

thank you in advance

← reply



**Melanie Ortiz** 5 months ago

SCImago Team

Dear Rafael,  
thank you very much for your comment.  
We suggest you consult the WoS database directly.  
Best Regards, SCImago Team



**Adel** 8 months ago

Why ACS-Omega does not recognized in Scopus. I published one paper in ACS-Omega.

← reply



**Rashford** 8 months ago

I asked them by using live chat support, and they confirmed that the journal is active and currently scopus indexed (2021).



**Melanie Ortiz** 8 months ago

SCImago Team

Dear Adel,  
Thank you very much for your comment.  
All the metadata have been provided by Scopus /Elsevier in their last update sent to SCImago, including the Coverage's period data. The SJR for 2019 was released on 11 June 2020. We suggest you consult the Scopus database directly to see the current index status as SJR is a static image of Scopus, which is changing every day.  
For further information, please contact Scopus support:  
[https://service.elsevier.com/app/answers/detail/a\\_id/14883/kw/scimago/supporthub/scopus/](https://service.elsevier.com/app/answers/detail/a_id/14883/kw/scimago/supporthub/scopus/)  
Best Regards, SCImago Team



**ATIQAHA** 10 months ago

Hi, is ACS Omega need to pay for the page charge?

← reply





**Melanie Ortiz** 10 months ago

SCImago Team

Dear Atiqah,  
thank you for contacting us.  
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.  
Best Regards, SCImago Team

N

**nashwa** 1 year ago

is ACS Omega scopus or thomson?

← reply

M

**Massoud Kaykhali** 10 months ago

Both!



**Melanie Ortiz** 1 year ago

SCImago Team

Dear Nashwa,  
Thank you very much for your comment.  
All the metadata have been provided by Scopus /Elsevier in their last update sent to SCImago, including the Coverage's period data. The SJR for 2019 was released on 11 June 2020. We suggest you consult the Scopus database directly to see the current index status as SJR is a static image of Scopus, which is changing every day.  
Best Regards, SCImago Team

H

**Hamid** 2 years ago

Dear sir,  
ACS Omega Q1 or Q2?  
I saw at web of science that ACS Omega is Q2

← reply

You can see that information just above (see Quartiles). Best Regards, SCImago Team

C

**chen** 2 years ago

Is ACS Omega a paid journal?. Have we pay money for manuscript publications?.'

← reply

**Melanie Ortiz** 2 years ago

SCImago Team

Dear user,

thank you for contacting us.

Sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.

Unfortunately, we cannot help you with your request, we suggest you to visit the journal's homepage oYou can see the updated journal's information just above .

Best Regards, SCImago Team

D

**Dylan Rogers** 3 years ago

What is the impact factor of this journal? I cannot find. Please help.

← reply

**Elena Corera** 3 years ago

SCImago Team

Dear Dylan, SCImago Journal and Country Rank uses Scopus data, our impact indicator is the SJR. Check our page to locate the journal. We suggest you consult the Journal Citation Report for other indicators (like Impact Factor) with a Web of Science data source. Best Regards, SCImago Team

**Leave a comment**

Name

Email

(will not be published)

Stop seeing this ad

Why this ad? ⓘ

reCAPTCHA

Could not connect to the reCAPTCHA service.

Please check your internet connection and reload to get a reCAPTCHA challenge.

[Privacy](#) - [Terms](#)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2020. Data Source: Scopus®






Ads by Google

Stop seeing this ad

Why this ad? ⓘ



# Source details

## ACS Omega

Open Access ⓘ

Scopus coverage years: from 2016 to Present

Publisher: American Chemical Society

E-ISSN: 2470-1343

Subject area: Chemical Engineering: General Chemical Engineering Chemistry: General Chemistry

Source type: Journal

CiteScore 2021 ⓘ  
**5.2**

SJR 2021 ⓘ  
**0.708**

SNIP 2021 ⓘ  
**0.894**

[View all documents >](#) [Set document alert](#) [Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### Improved CiteScore methodology

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

### CiteScore 2021 ▼

$$5.2 = \frac{58,469 \text{ Citations 2018 - 2021}}{11,320 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

### CiteScoreTracker 2022 ⓘ

$$5.8 = \frac{79,457 \text{ Citations to date}}{13,624 \text{ Documents to date}}$$

Last updated on 05 April, 2023 • Updated monthly

### CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Chemical Engineering		
General Chemical Engineering	#75/280	73rd
Chemistry		
General Chemistry	#119/409	71st

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site &#x262f;](#)

---

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.



---

## Decision on an-2021-00423k

2 messages

---

**ACS Applied Nano Materials** <onbehalf@manuscriptcentral.com>

Wed, Feb 17, 2021 at 5:16 AM

Reply-To: lee-office@anm.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: trlee@anm.acs.org

16-Feb-2021

Journal: ACS Applied Nano Materials

Manuscript ID: an-2021-00423k

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Author(s): Aung, Yu Yu; Kristanti, Alfinda Novi; Lee, Hwei V.; Fahmi, Mochamad

Dear Prof. Dr. Fahmi:

Thank you for submitting your revised manuscript to be considered for publication in ACS Applied Nano Materials. I examined your revised manuscript and your letter of response. Regrettably, you have failed to revise your manuscript to address adequately the previous concerns that were raised. Moreover, the quality of the writing and graphics is below the standards of the journal. Given these considerations and the potential impact of the work as a whole, I regret to inform you that I am unable to accept the manuscript for publication.

I am pleased, however, to provide an opportunity to submit your manuscript to ACS Omega. To have your manuscript files and information copied to a new submission for ACS Omega, please see the information below. The editors at ACS Omega will evaluate your revised manuscript from a fresh perspective. Please note that submitting your manuscript to ACS Omega comes with no guarantee of acceptance or external review.

If you wish to submit a revised manuscript to ACS Omega, please ensure that revised manuscript addresses each of the comments below. Specifically, please include a point-by-point response to each of the editor comments, a description of the changes you have made along with a description of where the changes can be found, and a marked copy of the revised manuscript that clearly highlights the changes made in revision. Notably, the content of your point-by-point responses must be incorporated into the revised manuscript.

The editors at ACS Omega encourage you to consider the recommendations received from ACS Applied Nano Materials. Specifically, I recommend that the following issue(s) be addressed in your revised manuscript before submission to ACS Omega:

1) The overall quality of the graphics is below ACS standards; exceptional improvements in style, clarity, contrast, and sharpness are needed for all of the figures and schemes.

2) Please redraw all chemical structures in the manuscript so that they have proper bond lengths and angles and conform to the standard ACS ChemDraw settings. To find the standard ACS ChemDraw settings: in the ChemDraw program under the "Object" tab, select "Apply object settings from ACS Document 1996".

2) Please add scale bars to Figures 10 and 12.

3) Please revise and substantially simplify the Table of Contents graphic so that all components (including text) can be easily seen when reduced in size to the required dimensions (8.25 cm wide by 4.45 cm tall). Notably, the width must be greater than the height. For guidance on the Table of Contents graphic, see <https://pubs.acs.org/doi/10.1021/nn203713e>.

4) Please improve the clarity/resolution of all of the TOC graphic.

5) TOC graphic cannot be the same as Scheme 1 or any other graphic.

6) There are too many graphics and tables in the text of the manuscript. Please reduce the total number of graphics and tables in the text to twenty or preferably less by moving the least critical data to Supporting Information. Removal of the

poorest quality graphics is particularly needed.

7) The writing must be improved. Please seek the help of a native speaker of English to improve the prose and grammar. Professional English editors can be contacted at: [http://pubs.acs.org/page/4authors/tools/language\\_editing.html](http://pubs.acs.org/page/4authors/tools/language_editing.html).

Thank you again for your interest in ACS Applied Nano Materials.

Sincerely,

Prof. T. Randall Lee  
Deputy Editor  
ACS Applied Nano Materials  
Office: 919-259-3046  
[lee-office@anm.acs.org](mailto:lee-office@anm.acs.org)  
[eic@anm.acs.org](mailto:eic@anm.acs.org)

Transfer Manuscript Options:

ACS Omega (<http://pubs.acs.org/journal/acsodf>) is the open access journal for rapid publication of quality articles in chemistry and interfacing areas of science. The journal offers expedited editorial decision-making and is free to read for everyone. Please note that should your manuscript be accepted by ACS Omega, there is an article publishing charge of \$1,250 that covers any of the open-access license options (including CC-BY, for authors who require or prefer this option). Corresponding authors based in countries listed at <https://acsopencscience.org/country-discounts/> qualify for additional discounts. Additionally, corresponding authors who are not already members of the American Chemical Society will receive a one-year ACS membership.

To transfer your manuscript to ACS Omega, please approve the transfer via the link below:

Approve transfer: \*\*\* PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. \*\*\*

[https://acs.manuscriptcentral.com/acs-an?URL\\_MASK=84da2c17376b438dbb6110d06492ca19](https://acs.manuscriptcentral.com/acs-an?URL_MASK=84da2c17376b438dbb6110d06492ca19)

When you choose to transfer, ACS Paragon Plus will copy your manuscript files and submission information to create a new draft submission for ACS Omega. The submission will appear on the My Authoring Activity tab in the Transferred Manuscripts queue under "Transferred Manuscripts Awaiting Submission". Please make any needed changes to the manuscript files and responses to the submission questions and complete the new submission to ACS Omega in ACS Paragon Plus.

In order to expedite processing at ACS Omega, please include in the cover letter your detailed response to the comments made by the reviewers and editor, in addition to making appropriate revisions to the manuscript text and/or figures to address their comments.

Each ACS publication is independent with respect to all editorial decisions. When a manuscript is transferred, the reviews, reviewer identities, and decision letter will also be transferred to the new journal. Additional information about the manuscript transfer process is available at [http://pubs.acs.org/page/policy/manuscript\\_transfer/index.html](http://pubs.acs.org/page/policy/manuscript_transfer/index.html).

If you do not want to transfer this manuscript to ACS Omega, please decline via the link below:

Decline transfer: \*\*\* PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. \*\*\*

[https://acs.manuscriptcentral.com/acs-an?URL\\_MASK=c1f9992b098542e0aa5c81ea0daa4f3d](https://acs.manuscriptcentral.com/acs-an?URL_MASK=c1f9992b098542e0aa5c81ea0daa4f3d)

-----  
FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:  
ACS Publications Customer Services & Information (CSI)  
Email: [support@services.acs.org](mailto:support@services.acs.org)  
Phone: 202-872-4357  
Toll-Free Phone: 800-227-9919 (USA/Canada only)



-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

**Mochamad Zakki Fahmi** <[m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)>  
To: yuyu aung <[yuyuaung85@gmail.com](mailto:yuyuaung85@gmail.com)>

Wed, Feb 17, 2021 at 7:54 AM

yu ACS APPLIED NANO reject the paper an transfeed ti acs omega with some comment from the editor. please do modification folowingvtej commnet below

[Quoted text hidden]

--

Best Regards,

-----

Mochamad Zakki Fahmi, Ph.D (張家其)  
Assistant Professor, Departement of Chemistry  
Airlangga University  
Phone : +62-838-32901697  
Email : [m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)

**Fahmi, Mochamad ao-2021-013526 - Manuscript Submission to ACS Omega 13-Mar-2021**

1 message

**ACS Omega** <onbehalf@manuscriptcentral.com>

Sat, Mar 13, 2021 at 6:22 PM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

13-Mar-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu Yu; Kristanti, Alfinda Novi; Lee, Hwei V.; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully transferred to ACS Omega.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by selecting the tab labeled "My Authoring Activity" in ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

**Journal Publishing Agreement and Copyright**

Upon acceptance, ACS Publications will require the corresponding author to sign and submit a Journal Publishing Agreement. This agreement gives authors a number of rights regarding the use of their manuscripts. At acceptance, the corresponding author will receive an email linking through to the Journal Publishing Agreement Wizard, which helps you select the most appropriate license for your manuscript.

For more information please see: [https://pubs.acs.org/page/copyright/journals/jpa\\_faqs.html](https://pubs.acs.org/page/copyright/journals/jpa_faqs.html)

**ACS Authoring Services**

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang  
ACS Omega

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubsupdates@acs.org](mailto:Pubsupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526 - Manuscript Revision Request 07-Apr-2021

2 messages

---

**ACS Omega** <onbehalf@manuscriptcentral.com>  
Reply-To: Zhang-office@omega.acs.org  
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Wed, Apr 7, 2021 at 12:53 PM

07-Apr-2021

Journal: ACS Omega  
Manuscript ID: ao-2021-013526  
Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"  
Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

COVID-19 Support: Please visit the following website to access important information for ACS authors and reviewers during the COVID-19 crisis: <https://axial.acs.org/2020/03/25/chemists-covid-19-coronavirus/>

We are flexible in these unprecedented times affecting the global research community. If you need more time to complete authoring or reviewing tasks, please contact the editorial office and request an extension.

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been examined by expert reviewers. In its current form, your manuscript is not suitable for publication in ACS Omega. The reviewers have raised points that require significant consideration. However, with an adequate point-by-point response and the appropriate revisions, your paper may become acceptable for publication.

We would like to receive your revision no later than 28-Apr-2021. The revision should address the reviewers' comments and include a point-by-point response. Your manuscript will be subject to further peer review.

Please note that you will receive a follow-up message within 24 hours describing the non-scientific changes you must make to your manuscript before you submit the revision.

To revise your manuscript, log into ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

When submitting your revised manuscript through ACS Paragon Plus, you will be able to respond to the comments made by the reviewer(s) in the text box provided or by attaching a file containing your detailed responses to all of the points raised by the reviewers.

Please upload manuscript file that is free of any annotations or highlights.

Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See [http://pubs.acs.org/page/4authors/funder\\_options.html](http://pubs.acs.org/page/4authors/funder_options.html) for complete instructions.

ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before

completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at <http://www.orcid.org>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

We look forward to seeing your paper in ACS Omega.

Sincerely,

Dr. Deqing Zhang  
Coeditor  
ACS Omega  
Phone: +86-10-62639355  
Fax: (202) 559-0879  
Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

-----  
Reviewer(s)' Comments to Author:

Reviewer: 1

Recommendation: Publish after major revisions.

Comments:

The manuscript summarized boron based nanomaterials and their biomedical application. Boron modified nanomaterials displayed intriguing features, yet, the authors needs to summarize them in a more logical way. A major revision was required before further consideration. Followings are issues that need to be addressed properly.

Q1. The scheme figure is a bit problematic. Glucose sensor is one of the aspect of biosensing. Cancer is a disease and not suitable for representing one of biomedical application of boronic acids. It can be either cancer diagnosis or treatment, rather than simple cancer. Particularly in Section 3, the content needs to be categorized.

Q2. All the format of figure captions shall be consistent. Apparently, the figure caption of Scheme 3 is different with others.

Q3. Some of the statements is verbose. The authors need to summarize the progress of boronic acid based nanomaterials. For example, in section 3.3, some of the content needs to combined together as boronic acid based nanomaterial for fluorescent sensors.

Q4. The knowledge of boron including its Lewis acidity have been extensively reviewed in the past decades. The authors should put emphasis on the unique features of boron based nanomaterials. Thus, Section 1 could be more concise.

Q5. For Section 2.1, I suggest more discussion shall be focused on the current methods for preparing boron modified nanoparticles and summarized the effect of the different doping on the properties of nanomaterials.

Q6. Section 5.1 seems to focus on boronic acid modified polymer, which may be not related to the topic of boron modified nanomaterials.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: In Part (Please Elaborate in Your Review)

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

Reviewer: 2

Recommendation: Publish after major revisions.

Comments:

The authors summarized boronic acid-modified nanomaterials for a variety of biomedical applications, such as bioimaging, biosensing, and antiviral effects. There are the following comments in below. The reviewer recommends that the manuscript should be carefully revised and the current version is not suitable for publication.

< Major comments >

1. Introduction: The authors should cite this reference (SH Hong, M Shin et al, Adv. Funct. Mater. 2019, 26) to mention dynamic supramolecular assembly between boronic acid and diol groups. Also, please cite recent reference (Materials Science and Engineering: C, Volume 71, 1 February 2017, Pages 1064-1071).
2. The section 2 is not sufficient. For instance, the authors only explained the section 2.1 of "Boron modified Carbon dots". The authors should add more sections in detail to include the subsections of GQD, CQD and PDs.
3. The section 5 should be reorganized. The authors focused on boronic acid modified nanomaterials in overall manuscript, but the section 5 included general materials like polymers as antiviral agents.

< Minor comments >

4. Please provide full names before using the abbreviation.
5. Page 7, Line 22: Boronic acid analogue with carboxylic acid, which it can serve as proton donor. -> Boronic acid derivatives with carboxylic acid can serve as proton donor.
6. Page 17, Line 22: CD -> Carbon dots
7. There are many typos and grammatical errors. The authors should use language editing services.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

Reviewer: 3

Recommendation: Publish after major revisions.

Comments:

One of the biggest issue is that there are inter-connection and the interrelated significance between each the cited articles are not easy to appreciate. This makes the article to be a "fragmented article". I would have to be carefully saying that this could be due to that my expertise on bio-science not deep enough, or that the writing flow is indeed not well constructed. The writing style seems not consistent from paragraph to paragraph.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: No

Are the literature references appropriate and up to date?: Yes

-----  
FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:  
ACS Publications Customer Services & Information (CSI)  
Email: [support@services.acs.org](mailto:support@services.acs.org)  
Phone: 202-872-4357  
Toll-Free Phone: 800-227-9919 (USA/Canada only)



-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

**Mochamad Zakki Fahmi** <[m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)>  
To: yu yu <[yu.yu.aung-2018@fst.unair.ac.id](mailto:yu.yu.aung-2018@fst.unair.ac.id)>

Thu, Apr 8, 2021 at 8:01 AM

yu please resposne all comments for your reviewed paper below

[Quoted text hidden]

--

Best Regards,

-----

Mochamad Zakki Fahmi, Ph.D (張家其)  
Assistant Professor, Departement of Chemistry  
Airlangga University  
Phone : +62-838-32901697  
Email : [m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)

---

## Fahmi, Mochamad ao-2021-013526 Assigned to Editor 19-Mar-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Fri, Mar 19, 2021 at 6:11 PM

Reply-To: Ganesh-office@omega.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

19-Mar-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Author(s): Aung, Yu Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Associate Editor Assigned

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been assigned to the following editor:

Dr. Deqing Zhang

Coeditor

ACS Omega

Phone: +86-10-62639355

Fax: (202) 559-0879

Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

Please address all future correspondence regarding this manuscript to the above editor.

Submission of a manuscript to ACS Omega implies that the work reported therein has not received prior publication and is not under consideration for publication elsewhere in any medium, including electronic journals and computer databases of a public nature. This manuscript is being considered with the understanding that it is submitted on an exclusive basis. If otherwise, please advise.

Also please note that according to ACS Ethical Guidelines to Publication of Chemical Research, all authors must have reviewed and approved the submission of their manuscript. If you are a coauthor and approve its submission, no action is necessary. Similarly coauthors must approve the appointment of a Corresponding Author to select and execute the appropriate ACS publishing agreement, and should be informed by the Corresponding Author of the terms and conditions of that agreement. If you do not approve its submission to ACS Omega or the selection of Corresponding Author, please let us know as soon as possible. Refer to the manuscript number listed above in any correspondence, or you may simply reply to this message leaving the subject line intact. For more information on ethical responsibilities of authors, see the Ethical Guidelines to Publication of Chemical Research at <http://pubs.acs.org/page/policy/ethics/index.html>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

Sincerely,

Dr. Krishna Ganesh  
Coeditor  
ACS Omega  
Phone: (202) 657-6323  
Email: [Ganesh-office@omega.acs.org](mailto:Ganesh-office@omega.acs.org)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R1 - Manuscript Revision Request 06-May-2021

2 messages

---

**ACS Omega** <onbehalf@manuscriptcentral.com>  
Reply-To: Zhang-office@omega.acs.org  
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Thu, May 6, 2021 at 1:18 PM

06-May-2021

Journal: ACS Omega  
Manuscript ID: ao-2021-013526.R1  
Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"  
Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

COVID-19 Support: Please visit the following website to access important information for ACS authors and reviewers during the COVID-19 crisis: <https://axial.acs.org/2020/03/25/chemists-covid-19-coronavirus/>

We are flexible in these unprecedented times affecting the global research community. If you need more time to complete authoring or reviewing tasks, please contact the editorial office and request an extension.

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been examined by expert reviewers. In its current form, your manuscript is not suitable for publication in ACS Omega. The reviewers have raised points that require significant consideration. However, with an adequate point-by-point response and the appropriate revisions, your paper may become acceptable for publication.

We would like to receive your revision no later than 27-May-2021. The revision should address the reviewers' comments and include a point-by-point response. Your manuscript will be subject to further peer review.

Please note that you will receive a follow-up message within 24 hours describing the non-scientific changes you must make to your manuscript before you submit the revision.

To revise your manuscript, log into ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

When submitting your revised manuscript through ACS Paragon Plus, you will be able to respond to the comments made by the reviewer(s) in the text box provided or by attaching a file containing your detailed responses to all of the points raised by the reviewers.

Please upload manuscript file that is free of any annotations or highlights.

Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See [http://pubs.acs.org/page/4authors/funder\\_options.html](http://pubs.acs.org/page/4authors/funder_options.html) for complete instructions.

ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before

completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at <http://www.orcid.org>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

We look forward to seeing your paper in ACS Omega.

Sincerely,

Dr. Deqing Zhang  
Coeditor  
ACS Omega  
Phone: +86-10-62639355  
Fax: (202) 559-0879  
Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

-----  
Reviewer(s)' Comments to Author:

Reviewer: 1

Recommendation: Publish after major revisions.

Comments:

Though part of the maintext was revised according to the suggestions by the revieweres. Still the authors need to well construct the whole manuscript. Inter-connection and interrelated category stardard exsits. Scheme 1 is also need to be revised, where glucose sensor is part of biosensing. Cancer and diagnosis is part of biomedical applications.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: No

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

Reviewer: 2

Recommendation: Publish as is; no revisions needed.

Comments:

The authors responded to solve all issues raised by the reviewer.  
Now, I recommend acceptance of this paper in this journal.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes



Are the literature references appropriate and up to date?: Yes

-----  
FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:

ACS Publications Customer Services & Information (CSI)

Email: [support@services.acs.org](mailto:support@services.acs.org)

Phone: 202-872-4357

Toll-Free Phone: 800-227-9919 (USA/Canada only)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

**Mochamad Zakki Fahmi** <[m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)>

Thu, May 6, 2021 at 1:46 PM

To: [yu.yu.aung-2018@fst.unair.ac.id](mailto:yu.yu.aung-2018@fst.unair.ac.id)

Yu response the 1 comment of reviewer for your last paper

**Best Regards,**

-----  
**Mochamad Zakki Fahmi, Ph.D (張家其)**  
**Associate Professor, Department of Chemistry**  
**Universitas Airlangga**  
**Phone : +62-838-32901697**  
**Email : [m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)**



[Quoted text hidden]

---

## Fahmi, Mochamad ao-2021-013526.R1 - Revised Manuscript Submission to ACS Omega 24-Apr-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Sat, Apr 24, 2021 at 3:09 PM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

24-Apr-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R1

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

### ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang  
ACS Omega

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it

to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R1 Assigned to Editor 24-Apr-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Sat, Apr 24, 2021 at 3:09 PM

Reply-To: Ganesh-office@omega.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

24-Apr-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R1

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Associate Editor Assigned

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been assigned to the following editor:

Dr. Deqing Zhang

Coeditor

ACS Omega

Phone: +86-10-62639355

Fax: (202) 559-0879

Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

Please address all future correspondence regarding this manuscript to the above editor.

Submission of a manuscript implies that the work reported therein has not received prior publication and is not under consideration for publication elsewhere in any medium, including electronic journals and computer databases of a public nature. This manuscript is being considered with the understanding that it is submitted on an exclusive basis. If otherwise, please advise.

Also please note that according to ACS Ethical Guidelines to Publication of Chemical Research, all authors must have reviewed and approved the submission of their manuscript. If you are a coauthor and approve its submission, no action is necessary. Similarly coauthors must approve the appointment of a Corresponding Author to select and execute the appropriate ACS publishing agreement, and should be informed by the Corresponding Author of the terms and conditions of that agreement. If you do not approve its submission to ACS Omega or the selection of Corresponding Author, please let us know as soon as possible. Refer to the manuscript number listed above in any correspondence, or you may simply reply to this message leaving the subject line intact. For more information on ethical responsibilities of authors, see the Ethical Guidelines to Publication of Chemical Research at <http://pubs.acs.org/page/policy/ethics/index.html>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

Sincerely,

Dr. Krishna Ganesh  
Coeditor  
ACS Omega  
Phone: (202) 657-6323  
Email: [Ganesh-office@omega.acs.org](mailto:Ganesh-office@omega.acs.org)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.



---

## Fahmi, Mochamad ao-2021-013526.R2 - Revised Manuscript Submission to ACS Omega 10-May-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Tue, May 11, 2021 at 10:29 AM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

10-May-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R2

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

### ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang  
ACS Omega

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it

to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R2 Assigned to Editor 10-May-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Tue, May 11, 2021 at 10:29 AM

Reply-To: Ganesh-office@omega.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

10-May-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R2

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Associate Editor Assigned

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been assigned to the following editor:

Dr. Deqing Zhang

Coeditor

ACS Omega

Phone: +86-10-62639355

Fax: (202) 559-0879

Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

Please address all future correspondence regarding this manuscript to the above editor.

Submission of a manuscript implies that the work reported therein has not received prior publication and is not under consideration for publication elsewhere in any medium, including electronic journals and computer databases of a public nature. This manuscript is being considered with the understanding that it is submitted on an exclusive basis. If otherwise, please advise.

Also please note that according to ACS Ethical Guidelines to Publication of Chemical Research, all authors must have reviewed and approved the submission of their manuscript. If you are a coauthor and approve its submission, no action is necessary. Similarly coauthors must approve the appointment of a Corresponding Author to select and execute the appropriate ACS publishing agreement, and should be informed by the Corresponding Author of the terms and conditions of that agreement. If you do not approve its submission to ACS Omega or the selection of Corresponding Author, please let us know as soon as possible. Refer to the manuscript number listed above in any correspondence, or you may simply reply to this message leaving the subject line intact. For more information on ethical responsibilities of authors, see the Ethical Guidelines to Publication of Chemical Research at <http://pubs.acs.org/page/policy/ethics/index.html>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

Sincerely,

Dr. Krishna Ganesh  
Coeditor  
ACS Omega  
Phone: (202) 657-6323  
Email: [Ganesh-office@omega.acs.org](mailto:Ganesh-office@omega.acs.org)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R3 - Revised Manuscript Submission to ACS Omega 15-May-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Sat, May 15, 2021 at 11:00 AM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

15-May-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R3

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

### ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang  
ACS Omega

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it

to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.



---

## Fahmi, Mochamad ao-2021-013526.R3 Assigned to Editor 15-May-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Sat, May 15, 2021 at 11:00 AM

Reply-To: Ganesh-office@omega.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

15-May-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R3

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Associate Editor Assigned

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been assigned to the following editor:

Dr. Deqing Zhang

Coeditor

ACS Omega

Phone: +86-10-62639355

Fax: (202) 559-0879

Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

Please address all future correspondence regarding this manuscript to the above editor.

Submission of a manuscript implies that the work reported therein has not received prior publication and is not under consideration for publication elsewhere in any medium, including electronic journals and computer databases of a public nature. This manuscript is being considered with the understanding that it is submitted on an exclusive basis. If otherwise, please advise.

Also please note that according to ACS Ethical Guidelines to Publication of Chemical Research, all authors must have reviewed and approved the submission of their manuscript. If you are a coauthor and approve its submission, no action is necessary. Similarly coauthors must approve the appointment of a Corresponding Author to select and execute the appropriate ACS publishing agreement, and should be informed by the Corresponding Author of the terms and conditions of that agreement. If you do not approve its submission to ACS Omega or the selection of Corresponding Author, please let us know as soon as possible. Refer to the manuscript number listed above in any correspondence, or you may simply reply to this message leaving the subject line intact. For more information on ethical responsibilities of authors, see the Ethical Guidelines to Publication of Chemical Research at <http://pubs.acs.org/page/policy/ethics/index.html>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

Sincerely,

Dr. Krishna Ganesh  
Coeditor  
ACS Omega  
Phone: (202) 657-6323  
Email: [Ganesh-office@omega.acs.org](mailto:Ganesh-office@omega.acs.org)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R4 - Manuscript Revision Request - Formatting Changes 28-May-2021

3 messages

---

**ACS Omega** <onbehalf@manuscriptcentral.com>  
Reply-To: Zhang-office@omega.acs.org  
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Fri, May 28, 2021 at 6:51 PM

28-May-2021

Journal: ACS Omega  
Manuscript ID: ao-2021-013526.R4  
Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"  
Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

COVID-19 Support: Please visit the following website to access important information for ACS authors and reviewers during the COVID-19 crisis: <https://axial.acs.org/2020/03/25/chemists-covid-19-coronavirus/>

We are flexible in these unprecedented times affecting the global research community. If you need more time to complete authoring or reviewing tasks, please contact the editorial office and request an extension.

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega.

Unfortunately, the number of references on your latest version of the manuscript is not acceptable. Please kindly reduce the number of references according to the guidelines for mini-review papers of ACS Omega. Please note that since this is a mini-review manuscript type only important references can be cited. Otherwise, the editor will consider to change the decision.

In addition, please perform the following formatting changes:

- It has been noted that  
SCHEME 2.  
FIGURE 1-5  
FIGURE 7-14  
FIGURE 16-17  
Figure S2

contain referenced materials. Kindly note that any graphic (figure chart, scheme, or equation) that has appeared in an earlier publication should include a credit line citing the original source. If no credit line wording is included in the permission, create your own by using the following example, substituting the appropriate wording in place of the capitalized words:

Reprinted (Adapted or Reprinted in part) with permission from [COMPLETE REFERENCE CITATION]. Copyright [YEAR THAT THE MATERIAL YOU ARE USING WAS PUBLISHED BY THE PUBLISHER/COPYRIGHT OWNER] [NAME OF THE PUBLISHER/COPYRIGHT OWNER].

Authors are responsible for obtaining written permission to re-use such material.

Please upload necessary permissions for the above mentioned Schemes and Figures.

-----  
To revise your manuscript, log into ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

Please upload manuscript file that is free of any annotations or highlights.

Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry

tool in ACS Paragon Plus and in the manuscript to meet this requirement. See [http://pubs.acs.org/page/4authors/funder\\_options.html](http://pubs.acs.org/page/4authors/funder_options.html) for complete instructions.

ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at <http://www.orcid.org>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

We look forward to seeing your paper in ACS Omega.

Sincerely,

Dr. Deqing Zhang  
Coeditor  
ACS Omega  
Phone: +86-10-62639355  
Fax: (202) 559-0879  
Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

**Mochamad Zakki Fahmi** <[m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)>

Sat, May 29, 2021 at 6:30 AM

To: [yu.yu.aung-2018@fst.unair.ac.id](mailto:yu.yu.aung-2018@fst.unair.ac.id)

Yu reduce te reference up to 25

[Quoted text hidden]

--

Best Regards,

-----

Mochamad Zakki Fahmi, Ph.D (張家其)  
Assistant Professor, Departement of Chemistry  
Airlangga University  
Phone : +62-838-32901697  
Email : [m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)

---

**yu yu** <[yu.yu.aung-2018@fst.unair.ac.id](mailto:yu.yu.aung-2018@fst.unair.ac.id)>

Sat, May 29, 2021 at 11:03 AM

To: Mochamad Zakki Fahmi <[m.zakki.fahmi@fst.unair.ac.id](mailto:m.zakki.fahmi@fst.unair.ac.id)>

Baik Pak. I'll revise immediately it. Terima kasih Pak.

[Quoted text hidden]

---

## Fahmi, Mochamad ao-2021-013526.R4 - Revised Manuscript Submission to ACS Omega 25-May-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Tue, May 25, 2021 at 12:01 PM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

25-May-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R4

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

### ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang  
ACS Omega

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it



to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R4 Assigned to Editor 25-May-2021

1 message

---

**ACS Omega** <onbehalf@manuscriptcentral.com>

Tue, May 25, 2021 at 12:01 PM

Reply-To: Ganesh-office@omega.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

25-May-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R4

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Associate Editor Assigned

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been assigned to the following editor:

Dr. Deqing Zhang

Coeditor

ACS Omega

Phone: +86-10-62639355

Fax: (202) 559-0879

Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

Please address all future correspondence regarding this manuscript to the above editor.

Submission of a manuscript implies that the work reported therein has not received prior publication and is not under consideration for publication elsewhere in any medium, including electronic journals and computer databases of a public nature. This manuscript is being considered with the understanding that it is submitted on an exclusive basis. If otherwise, please advise.

Also please note that according to ACS Ethical Guidelines to Publication of Chemical Research, all authors must have reviewed and approved the submission of their manuscript. If you are a coauthor and approve its submission, no action is necessary. Similarly coauthors must approve the appointment of a Corresponding Author to select and execute the appropriate ACS publishing agreement, and should be informed by the Corresponding Author of the terms and conditions of that agreement. If you do not approve its submission to ACS Omega or the selection of Corresponding Author, please let us know as soon as possible. Refer to the manuscript number listed above in any correspondence, or you may simply reply to this message leaving the subject line intact. For more information on ethical responsibilities of authors, see the Ethical Guidelines to Publication of Chemical Research at <http://pubs.acs.org/page/policy/ethics/index.html>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

Sincerely,

Dr. Krishna Ganesh  
Coeditor  
ACS Omega  
Phone: (202) 657-6323  
Email: [Ganesh-office@omega.acs.org](mailto:Ganesh-office@omega.acs.org)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R5 - Manuscript Accepted 15-Jun-2021

1 message

---

**ACS Omega** <onbehalf@manuscriptcentral.com>  
Reply-To: Zhang-office@omega.acs.org  
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Tue, Jun 15, 2021 at 4:37 PM

15-Jun-2021

Journal: ACS Omega  
Manuscript ID: ao-2021-013526.R5  
Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"  
Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad  
Manuscript Status: Accept

Dear Dr. Fahmi:

We are pleased to inform you that your manuscript has been accepted for publication in ACS Omega.

You will soon receive an email invitation from the ACS Journal Publishing Staff that contains a link to the online Journal Publishing Agreement. Please sign and submit the journal publishing agreement within 48 hours.

You will be contacted in approximately a week by the ACS Journal Publishing Staff regarding the proofs for your manuscript. Although production of your manuscript will start immediately, your manuscript will not be published until you pay the Article Publishing Charges, <https://acsopencscience.org/open-access/pricing/>. You may qualify for discounts. You will also be contacted shortly with information on how to pay your publishing charges. Article Publishing Charges are waived for invited Editorials and Perspectives.

After you submit corrections for your proofs and pay the article publishing charges, your manuscript will be published on the Web in approximately 48 hours. In view of this fast publication time, it is important to review your proofs carefully. Once a manuscript appears on the Web, it is considered published. Any change to the manuscript once it appears on the Web will need to be submitted to the journal office as a separate Addition & Correction manuscript via the ACS Paragon Plus environment.

Once your paper is published, you can track downloads and citations of your work by logging into the ACS Publishing Center (<https://pubs.acs.org/publish/dashboard>) and selecting "Published."

Sincerely,

Dr. Deqing Zhang  
Coeditor  
ACS Omega  
Phone: +86-10-62639355  
Fax: (202) 559-0879  
Email: [Zhang-office@omega.acs.org](mailto:Zhang-office@omega.acs.org)

-----  
PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubsupdates@acs.org](mailto:Pubsupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

---

## Fahmi, Mochamad ao-2021-013526.R5 - Revised Manuscript Submission to ACS Omega 09-Jun-2021

1 message

---

ACS Omega <onbehalf@manuscriptcentral.com>

Wed, Jun 9, 2021 at 5:20 PM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

09-Jun-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R5

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

### ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang  
ACS Omega

---

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it



to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at [Pubupdates@acs.org](mailto:Pubupdates@acs.org) if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.